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1 Introduction and aims 
 
Colorectal cancer (CRC) is the third most common form of cancer in the UK; 36,600 new cases were 
diagnosed in 2007 and there were 16,259 CRC-related deaths in 2008.(1) The aim of population-
based screening for CRC is to reduce mortality through both prevention (by the removal of 
adenomas) and earlier diagnosis of CRC. 
 
In 2004, Tappenden et al. produced a report to the English Bowel Cancer Screening Working Group 
which appraised the options for colorectal cancer screening evaluating cost-effectiveness, cost-utility 
and resource impact. (2, 3) This study used a mathematical model to compare screening options 
using the guaiac faecal occult blood test (gFOBT) or flexible sigmoidoscopy (FS) for different age 
groups. The report concluded that screening using FOBT and/or FS is potentially a cost-effective 
strategy for the early detection of colorectal cancer. This report LQIRUPHGWKH'HSDUWPHQWRI+HDOWK¶V
policy on bowel cancer screening in England. The Bowel Cancer Screening Programme (BCSP) 
commenced rollout in England in 2006 offering biennial screening with gFOBT to persons aged 60 ± 
69 years, and in 2009, rollout to include the 70-74 age group commenced.  
 
Since the original options appraisal, the ScHARR CRC screening model has been updated 
considerably. The model now uses a Bayesian approach with the Metropolis Hastings algorithm to 
jointly estimate the CRC natural history state transition parameters and gFOBT test characteristics.(4) 
This approach generates parameter estimates using the ScHARR CRC natural history and screening 
model, together with several data sources including CRC incidence in the absence of screening and 
data from the first round of screening. 
 
Since the original options appraisal, significant new data has become available: 
 Data from the first two rounds of the England BCSP is available, including approximately 1.9 
million gFOBT screening participants. 
 A large randomised UK trial of flexible sigmoidoscopy (FS) for ages 55 to 64 years reported 
findings at baseline FS in 2000 and 10 year CRC incidence and mortality in 2010. (5, 6) 
 Further data is now available on the sensitivity and specificity of the immunochemical FOBTs, 
which are thought to be more sensitive than guaiac FOBTs. 
 
This study reappraises the options for CRC screening in England using these new data sources. Data 
from the gFOBT BCSP and the FS trial is used to estimate the characteristics of FS and gFOBT 
(including test characteristics, complication rates, and uptake). A systematic review and meta-analysis 
of iFOBT test characteristics is undertaken, and data from the Italian iFOBT screening programme is 
used to inform the model. 
 
A sensitivity analysis was performed to determine the optimal age for once-only FS screening. 
The following screening strategies were evaluated: 
 Biennial guaiac FOBT for ages 60-74 
 Biennial immunochemical FOBT for ages 60-74 (with several different iFOBT thresholds) 
 FS once at optimal age/age 55 
 FS once at optimal age/age 55, then biennial FOBT (guaiac/immuno) for ages 60-74 
 FS once at optimal age/age 55, biennial FOBT (guaiac/immuno) for ages 60-74 for those not 
receiving FS 
 
For each of the screening options the following key outputs were calculated and presented: 
 Cost effectiveness (incremental cost per QALY gained) 
 Number of cases of cancer avoided 
 Endoscopy resource use requirements 
 Number of cancer deaths avoided and number of deaths caused by screening  
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2 Description of screening interventions  
2.1 Screening tests: guaiac faecal occult blood test (gFOBT) 
Description of test 
The faecal occult blood test (FOBT) detects non-visible blood in the faeces associated with colorectal 
cancer (CRC) and adenomas. The FOBT has been shown to be clinically and economically effective 
when used for CRC screening, and it was first used in the National Health Service (NHS) Bowel 
Cancer Screening Programme (BCSP) in England in 2006. (2, 7) However, it is not a perfect test; 
there will be some false positive and false negative results because blood and blood breakdown 
products may have causes other than CRC/adenomas, some CRC/adenomas will not bleed, and not 
all blood will be detected. The gFOBT is relatively cheap, straightforward to use, and not associated 
with any significant complications. Several different types and brands of test are available. The test 
can be rehydrated before processing, which has been shown to increase sensitivity.  
 
Pathways in gFOBT screening 
In the English BCSP, participants are sent an invitation letter and then a second letter including a 
screening test kit to be completed at home. An un-rehydrated gFOBT called a HemaScreen is used. 
The NHS BCSP does not require persons undergoing FOBT to partake in any dietary restrictions. The 
test requires 6 stool samples (2 from each of three separate bowel motions). The test kit is returned 
by mail and is processed in a laboratory to determine if the card samples are positive or negative for 
blood. In the English BCSP, persons with weak positive results are asked to complete up to two 
repeat tests. Figures 1 and 2 describe the referral algorithm and the screening pathways used in the 
NHS BCSP. Anyone with an abnormal result (positive result in figure) will be offered a colonoscopy. 
 
Figure 2.1.1: gFOBT referral algorithm used in NHS BCSP 
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Figure 2.1.2: England gFOBT screening pathways
 
 
 
 
2.2 Screening tests: immunochemical faecal occult blood test (iFOBT) 
In 2001, a class of occult blood tests called Faecal Immunochemical Tests was introduced. These 
tests detect the globin in faeces rather than haem. By detecting globin, the tests are both more 
sensitive and specific for lower gastrointestinal bleeding. The iFOBT is associated with a much lower 
retest rate compared to the gFOBT. 
 
The iFOBT Evaluation Report produced by the Centre for Evidence-based Purchasing concluded that 
the OC-Sensor/DIANA analyser was the most suitable system for the English BCSP. Hence this 
analysis will focus on the OC-Sensor test. The patient pathways for iFOBT screening are assumed to 
be the same as for gFOBT screening.  
 
 
2.3 Screening tests: flexible sigmoidoscopy (FS) 
Description of test 
Flexible sigmoidoscopy is a procedure used to visualise the sigmoid colon and rectum. Two-thirds of 
CRC and adenomas are located in the rectum and sigmoid colon, which can be examined by flexible 
sigmoidoscopy (FS). During a FS procedure, biopsies from abnormal-looking tissues are also taken in 
order to test for signs of disease.  
Return gFOBT
screening kit
LR adenomas No polypsHR adenomas
Weak positive 
gFOBT result
Repeat 
gFOBT
Invited to 
screening (sent 
kit in post)
Do not return gFOBT
screening kit
Do not attend 
COL
Strong positive 
gFOBT result
CRC
Negative 
gFOBT result
Attend 
colonoscopy
Refer to follow 
up (colonoscopy)
gFOBT result
CRC 
treatment
Invited to screening
Follow-up
Surveillance Discharge to 
routine screening
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Where possible, the implementation and pathways for a FS screening programme were taken from 
the methods used in the FS trial or from the pathways discussed at a Bowel Cancer Screening 
Committee (BCSC) workshop held in September 2010.(8)  Figure 2.3.1 describes the screening 
pathways used within the UK FS trial. 
 
Figure 2.3.1: Flexible sigmoidoscopy screening pathways (including data from UK FS trial) 
 
 
The FS workshop held in September 2010 made the following recommendations regarding the FS 
screening pathway: 
 pre-invitation letter sent to subject 
 scannable health questionnaire sent to subject 
 letter with FS appointment time (subject suitable for screening) 
 appointment confirmed via automated telephone service (with access to real person if 
required) 
 bowel preparation medical and consent form sent to subjects who have confirmed 
appointment 
 contact SSP - individuals with uncertain fitness for FS 
 failure because of poor bowel preparation: repeat procedure on same day  
 post-procedure information and discharge and patient feedback: apply current BCSP 
arrangements 
 FS endoscopist stop the procedure and refer for colonoscopy when examining 
intermediate/high risk groups as defined in BCSP guidelines (3 or more small adenomas or 
one adenoma >1cm/ 5 or more small adenomas or 3 adenomas with one >1cm)  
 surveillance: current BCSP arrangements should be extended to cover FS 
It is suggested that the assumptions and cost estimates used here could be updated when further 
details of FS screening implementation are decided.  
 
Attend FS 
40,621
Attend COL  
1,874
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HR find (HR 
polyps or CRC) 
1942+37
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LR polyps 
8,173
PP 8173
No polyps 
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CRC 114
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1,306
Later day 
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839
CRC -> CRC treatment
HR polyps -> Surveillance COL
LR polyps/no polyps -> discharge
Findings at FS 
examination
Post FS follow 
up received
Invited to FS 
screening 
57,099
Do not 
attend FS 
16,478
Do not 
attend 
COL 68
Single FS 
undertaken 
38,476
Referred for 
off-protocol 
reasons* 165
Do not attend 
COL 11
Attend 
COL  154
Straight 
to surgery  
37
CRC 26
HR polyps 8
LR polyps 3
CRC 0
HR polyps 14
LR polyps 140
Invited to FS 
screening
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The referral to follow-up diagnostic colonoscopy after FS is modelled to reflect the FS trial referral 
criteria rather than the BCSP guidelines which were suggested at the workshop. Table 2.3.1 shows 
that the FS trial referral criteria include an additional criterion, so are effectively a lower threshold for 
referral than the BSG guidelines. The NHS BCSP would like to consider the implications of the use of 
the BSG guidelines for referral from FS to colonoscopy. This would result in a lower sensitivity and 
higher specificity than seen in the FS trial. The number of important lesions which would be missed by 
)6LIWKH%6*JXLGHOLQHVZHUHXVHGLQVWHDGRIWKHµ%6*¶JXLGHOLQHVLVEHLQJLQYHVWLJDWHGE\:HQG\
Atkin. 
 
Table 2.3.1: Comparison of BSG surveillance guidelines and FS trial referral criteria 
British Society of Gastroenterology(BSG) guidelines for 
surveillance colonoscopy after removal of colorectal 
adenomatous polyps (9, 10)  
 
)6WULDOFULWHULDIRUUHIHUUDOWRFRORQRVFRS\µ%6*¶(11) 
 
 Low risk: Patients with only 1±2, small (<1 
cm) adenomas. 
 Intermediate risk: Patients with 3±4 small 
adenomas or at least one >1 cm 
 High risk: >5 adenomas OR >3 adenomas at 
least one of which is >1 cm. 
 Receive surveillance colonoscopy: 
               >= 3 adenomas or at least one >1 cm 
Any of the following: 
 Number >=3 
 size >=1 cm 
 histology: tubulovillous or villous 
 dysplasia: severe or malignant 
 20 or more hyperplastic polyps above the 
distal rectum 
 
 
2.4 Description of screening strategies under evaluation 
The following screening strategies will be evaluated: 
 Biennial guaiac FOBT for ages 60-74 
 Biennial immunochemical FOBT for ages 60-74 (with several different iFOBT thresholds) 
 FS once at optimal age/age 55 
 FS once at optimal age/age 55, then biennial FOBT (guaiac/immuno) for ages 60-74 
 FS once at optimal age/age 55, biennial FOBT (guaiac/immuno) for ages 60-74 for those not 
receiving FS 
  
 10 
 
 
3 Methods 
3.1 Colorectal cancer natural history model structure 
 
Evidence suggests that most CRC develops from adenomas in the lining of the bowel which is known 
as the adenoma-carcinoma sequence.(12) Various approaches can be taken to model the 
development of adenomas and CRC. These include modelling: the growth of individual adenomas; 
WKHQXPEHUVL]HW\SHORFDWLRQRIDGHQRPDVDQLQGLYLGXDO¶VSURJUHVVLRQIURPnon-advanced to 
DGYDQFHGDGHQRPDVDQLQGLYLGXDO¶VSURJUHVVLRQIURPORZ-risk to high-risk adenomas.  
 
The natural history of CRC can be modelled using a patient-level or a cohort model.(13) (14) A 
patient-level simulation gives greater flexibility in modelling disease natural history and management, 
allowing, for instance, easier implementation of surveillance colonoscopy DVDSDWLHQW¶VSDWKZD\VZLOO
depend on their past surveillance results).  A patient-level modelling approach will generally require 
more parameters and distributional assumptions than a cohort model. For example, a cohort 
modelling approach requires information on the average rate at which an adenoma would develop 
into a colorectal cancer, but a patient-level modelling approach would also require knowledge of the 
between-patient variation in this rate.  
 
There is considerable uncertainty surrounding several of the natural history parameters such as 
adenoma growth rates. A cohort modelling approach was used in preference to a patient-level model 
in this instance to reduce the number of assumptions required and to ensure that there was sufficient 
data available to inform the model parameters. This choice was based on previous experience with 
both methods in modelling colorectal cancer. A state transition model was used to simulate the life 
experience of a cohort of 30 year old individuals in the general population of England with normal 
epithelium through to the development of adenomas and colorectal cancer and subsequent death.   
 
 
3.1.1 Definition of health states 
Health states were defined according to an LQGLYLGXDO¶VWUXHXQGHUO\LQJKLVWRORJLFDOVWDWHCRC was 
divided into eight KHDOWKVWDWHVZKLFKGHVFULEHWKH'XNHV¶VWDJHV$-D and whether or not the CRC 
has been clinically diagnosed: preclinical/clinical. 
 
Individuals with adenomas can be classified in many different ways to reflect the size, type, number 
and location of adenomas present, but it is important that the choice of adenoma health states reflects 
the data available to inform the model. The current gFOBT screening programme in England records 
GHWHFWLRQUDWHVIRU³ORZ-ULVN´DQG³LQWHUPHGLDWHKLJK-ULVN´DGHQRPDVDVGHILQed by the current British 
Society of Gastroenterology (BSG) guidelines for endoscopic surveillance following adenoma 
removal.(9) 'HWHFWLRQUDWHVIURPWKH)6VFUHHQLQJWULDOZKLFKXVHWKLVFODVVLILFDWLRQLQWR³ORZ-ULVN´DQG
³LQWHUPHGLDWHKLJK-ULVN´DGHQRPDVZHUHDOVRREWDLQHG7he modelling uses this classification of 
adenomas to define two health states to describe individuals with adenomas. The ³high risk 
adenomas´ health state includes persons with at least 3 small adenomas or at least one adenoma of 
size >1cm (this includes the BSG intermediate and high risk surveillance categories). The ³low-risk 
adenomas´ health state includes persons with 1-2 small (<1cm) adenomas. These health states 
FRUUHVSRQGWRWKRVHXVHGWRGHWHUPLQHDQLQGLYLGXDO¶VVXUYHLOODQFHVWUDWHJ\, so this approach eases 
the modelling of surveillance. 
 
The model health states are: normal epithelium, low risk adenomas, high risk adenomas, preclinical 
&5&'XNHV¶VWDJHV$-'FOLQLFDO&5&'XNHV¶VWDJHV$-D, and dead. The health states and transitions 
included within the natural history model are shown in Figure 3.1.1.  
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Figure 3.1.1: Diagram of model structure 
 
3.1.2 Transition between health states 
The transitions between health states are presented in Figure 1. We define a sequence of annual 
transition probabilities between these states relating to CRC developing through the adenoma±
carcinoma sequence, as this is thought to be the natural history of most CRC.  In addition, we define 
DWUDQVLWLRQSUREDELOLW\IURPQRUPDOHSLWKHOLXPWR'XNHV¶$&5&WRDOORZIRUWKHK\SRWKHVLVWKDWD
proportion of cancers do not arise from adenomas (de novo cancers). For each cancer state we 
define the probability of being diagnosed through symptomatic presentation or chance detection, and 
this transition corresponds to moving from a preclinical to a clinical health state.  
 
There is evidence to suggest that adenoma growth rate varies with age. Brenner et al examined the 
results of 840,149 screening colonoscopies and found that the age gradient is much stronger for CRC 
incidence than for advanced adenoma prevalence, hence projected annual transition rates from 
advanced adenomas to CRC strongly increase with age. (15) The probability of developing a low risk 
adenoma, the transition probability from low to high risk adenoma, and the transition probability from 
hiJKULVNDGHQRPDWR'XNHV¶VWDJH$&5&ZHUH allowed to vary by age using a piecewise linear 
model whose parameter values were the transition probabilities at ages 30, 50,70,100.  
 
Transitions between the preclinical CRC states and from preclinical to clinical CRC are assumed to be 
independent of age. All persons may die of non-CRC causes, and this is modelled using age-specific 
mortality rates. 2QFHDSHUVRQLVGLDJQRVHGZLWK&5&WKHWUDQVLWLRQVEHWZHHQ'XNHV¶VWDJHVDUHQR
longer modelled and a stage-specific CRC relative survival rate is applied. In addition, preclinical 
stage D CRC may be fatal. Survival rates for clinical CRC stages A-D and preclinical stage D CRC is 
assumed to be dependent on the CRC stage at diagnosis and patient age.  
 
3.1.3 Location of adenomas and cancer 
Adenomas and CRC may develop in various locations within the colon and rectum. Little data was 
identified describing CRC/adenoma prevalence by location and age. A study by Yamaji et al analysed 
the records of a colonoscopic follow-up study on 2900 subjects after polypectomy. They describe the 
Normal Epithelium
Low risk adenomas
High risk adenomas
ƵŬĞƐ ?ZƉƌĞĐůŝŶŝĐĂů
ƵŬĞƐ ?ZƉƌĞĐůŝŶŝĐĂů
ƵŬĞƐ ?ZƉƌĞĐůŝŶŝĐĂů
Stage D CRC preclinical
Dead (CRC)
ƵŬĞƐ ?ZĐůŝŶŝĐĂů
ƵŬĞƐ ?ZĐůŝŶŝĐĂů
Stage D CRC clinical
ƵŬĞƐ ?ZĐůŝŶŝĐĂů
Dead (non-CRC)
Transition estimated within model calibration
Transition estimated directly from mortality data
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FKDQJHLQDGHQRPDORFDWLRQE\DJH³$OWKRXJKWKHUHPD\EHLQGLYLGXDOSUHGLOHFWLRQIRU right-side or 
left-side location of colorectal adenomas, aging tends to increase the number of adenomas in the 
right-side colon, while only modestly affecting those in the left-VLGHFRORQ´(16) We observed that the 
proportion of persons who only had adenomas in the proximal colon did not vary significantly by age; 
see Table 3.1.1. 
 
Table 3.1.1: Location of adenomas by age as reported by Yamaji et al 2007 
 
 
Table 3.1.2 shows incidence of cancer in the proximal and distal colon by age for newly diagnosed 
cases in England in 2007. Of diagnosed cases of CRC with known location, 62% are located in the 
distal colon and 38% in the proximal colon. Distal and proximal CRC may be associated with different 
likelihoods of displaying symptoms and receiving a diagnosis. Hence the difference in incidence 
between the proximal and distal colon is unlikely to accurately reflect the difference in prevalence 
between the distal and proximal colon. 
 
Table 3.1.2: CRC by age and location, registrations of newly diagnosed cases 2007  
 
 
3.1.4 Screening test sensitivity by location 
The sensitivity of a screening test may vary between the distal and the proximal colon. This gives two 
important considerations for the modelling of screening. Firstly, as CRC/adenoma location 
distributions vary by age, it follows that the overall sensitivity of a screening test may vary by age. 
Secondly, a screening test with significantly different proximal and distal sensitivity will impact the 
location distribution for remaining undetected CRC and adenomas. This in turn will impact on the 
detection rates seen at subsequent screens. Hence, adenoma/CRC location distribution and 
screening test sensitivity by location may be important considerations when modelling combined or 
repeated screening strategies. 
 
Age group
Adenomas located 
only in the left side 
colon and rectum
Adenomas located in 
both the left side and 
the right-side colon
Adenomas located 
only in the right-side 
colon
<40 59% 12% 30%
40-49 56% 15% 29%
50-59 43% 24% 34%
>=60 37% 34% 29%
Incidence Rates per 100,000 population
Age range  Proximal  Distal 
30-34 1.2           41% 1.4               51% 0.2              8% 45% 55%
35-39 2.1           39% 2.9               53% 0.4              8% 42% 58%
40-44 3.6           36% 5.6               56% 0.8              8% 39% 61%
45-49 5.5           29% 12.2             64% 1.4              7% 31% 69%
50-54 10.2         27% 25.6             67% 2.6              7% 29% 71%
55-59 18.2         27% 44.7             66% 5.3              8% 29% 71%
60-64 36.5         31% 70.8             61% 9.0              8% 34% 66%
65-69 57.9         31% 112.0           61% 15.1            8% 34% 66%
70-74 79.0         33% 143.4           59% 20.0            8% 36% 64%
75-79 115.8       37% 166.8           54% 28.8            9% 41% 59%
80-84 149.9       40% 181.1           49% 40.8            11% 45% 55%
85 and over 140.4       39% 165.6           46% 55.4            15% 46% 54%
All ages 20.7         34% 33.7             56% 5.7              10% 38% 62%
 Distal Colon 
(C18.7,C18.8,C19,C20) 
 Proximal Colon 
(C18.0-C18.6) 
CRC with known location
 Unknown location 
(C18.9) 
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The extent to which the CRC sensitivity of a screening test varies between the distal/proximal colon 
can be estimated by comparing the location distribution of screen detected CRC with that of prevalent 
CRC. As no data on the location distribution of prevalent CRC was available, data on the location 
distribution of CRC incidence was used. The use of incidence as a proxy for prevalence will introduce 
errors, as symptoms and diagnosis rates will vary by location. Hence this calculation is simply a crude 
estimate for illustrative purposes. Location specific sensitivities for CRC are estimated in Table 3.1.3. 
 
Table 3.1.3: Screening test CRC detection by location 
 
 
In the England gFOBT screening programme, 72% of CRC detected (with a known location) was 
found in the distal colon, compared to 66% of CRC incidence which is distal for this age group. Using 
this data we estimate that gFOBT has very similar sensitivity in the distal and proximal colon.  
 
Flexible sigmoidoscopy examines the distal colon only; however, a participant may be referred to 
colonoscopy following FS and colonoscopy may find lesions in both the proximal and distal colon. In 
the UK flexible sigmoidoscopy trial, 90% of all CRC detected at screening was found in the distal 
colon, compared to 69% of CRC incidence which is distal for this age group. This implies a significant 
difference between distal and proximal sensitivity which corresponds with the nature of the test.  A FS 
CRC sensitivity of 20% for the proximal colon implies that 20% of proximal CRC was associated with 
a distal adenoma which required referral to colonoscopy.  
 
Sensitivity at repeat screens 
The estimated location specific test sensitivities were used to examine the degree to which the overall 
sensitivity to CRC may vary between a first and a repeat screen. An initial distal:proximal CRC split of 
70:30 was assumed, and calculation details are presented in Table 3.1.4. This calculation estimated 
the maximum possible change in overall sensitivity, as it assumes that the CRC location distribution 
does not change in the time after the first screen to before the repeat screen. The gFOBT overall 
sensitivity to CRC did not vary significantly by first/repeat screen; however, FS overall sensitivity to 
CRC may be reduced to as little at 0.42 for a repeat screen. Hence modelling varying FS sensitivity 
by first/repeat screen is important for a strategy involving two or more FS screens. This estimate of 
minimum FS overall sensitivity to CRC for a repeat FS screen is used within a sensitivity analysis.  
 
Table 3.1.4: Estimated overall sensitivity at first/repeat screen incorporating location-specific 
sensitivities 
 
 
Data on detection rates in the distal/proximal colon for iFOBT is not available, so no conclusions can 
be reached on the sensitivity in the proximal and distal locations. 
  
Location-specific sensitivity to adenomas  
Data on the location of adenomas is very complex to report. The definition used for high risk 
adenomas (or advanced adenomas) refers to the whole colon.  An individual will often have 
Screening Distal Proximal Overall Distal* Proximal*
gFOBT BCSP data 72% 28% 60-69 66% 0.24 0.26      0.20      
FS trial data 90% 10% 55-64 69% 0.62 0.81      0.20      
*Formulae used in calculation: overall sensitivity = proportion distal * distal sensitivity + proportion proximal * proximal sensitivity
Sensitivity to CRCScreen detected CRC Proportion of CRC incidence in 
distal colon for age group
Age group 
screened
Distal Proximal Distal Proximal Overall
gFOBT First screen 0.70           0.30           0.26 0.20      0.24   
Repeat screen 0.68           0.32           0.26 0.20      0.24   
FS First screen 0.70           0.30           0.81 0.20      0.63   
Repeat screen 0.36           0.64           0.81 0.20      0.42   
CRC location distribution Sensitivity to CRC
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adenomas in both the proximal and distal colon, and it may be the combination of these that 
determines the risk level. 
 
Yamaji et al found that the proportion of persons who only had adenomas in the proximal colon did 
not vary significantly by age; see Table 3.1.1. (16) Hence, even though the sensitivity of FS varies 
significantly between the proximal and the distal colon, this suggests that the overall sensitivity of FS 
may not significantly vary by age. 
 
Data from gFOBT screening showed a significantly lower HR adenoma detection rate at the repeat 
screen. This may suggest that the location specific variation in gFOBT HR adenoma sensitivity is 
significant. However, data on HR adenoma prevalence by location is not available, so this remains an 
area requiring further research. 
 
Further data on the location of CRC and adenomas detected at screening would allow more accurate 
modelling of location specific test characteristics in the future. In particular, data on location of screen 
detected CRC in iFOBT and colonoscopy screening would be valuable. 
3.1.5 Gender- and location-specific natural history model 
Future work could use different natural history model parameters for male and female and the distal 
and proximal colon. This would make the model structure more accurate, but such a model would 
require significantly more data to avoid adding additional unobservable input parameters. Screening 
data reporting detection rates for males and females separately and detailing the most advanced 
adenoma present in the proximal and distal colon would be required. The current model has a 
classification into four health states: normal epithelium, LR/HR adenomas and CRC stages A-D. 
However, when the most advanced lesion in both the proximal and distal colon is taken into 
consideration, this would require a large number of health states.  
 
 
3.1.6 Metachronous adenomas ± adenoma recurrence rates post-polypectomy 
The model uses data on the risk of recurrence of adenomas in persons who have had adenomas 
removed by polypectomy and are undergoing surveillance. To ensure consistency between the model 
parameters, it is important that the post-polypectomy transition probabilities used align with the other 
natural history transition probabilities in the model. We assume that persons who are undergoing 
surveillance post-polypectomy are at higher risk of developing adenomas than persons with a normal 
epithelium. We also assume that polypectomy reduces the risk of developing CRC. Hence we place 
restrictions on the post-polypectomy transition probabilities as described in Table 3.1.5. 
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Table 3.1.5: Restrictions on transition probabilities post-polypectomy
 
 
Data on the surveillance results from the England gFOBT BCSP details over 4000 surveillance 
colonoscopies. Unfortunately, data which details the results of 1 and 3 year (IR/HR) surveillance 
separately is not currently available, so some assumptions had to be made. 
 
Table 3.1.6: Detection rates at surveillance in the England gFOBT screening programme 
 
 
There is currently no data available of recurrence rates for persons with LR adenomas who do not 
receive surveillance in the English BCSP. 
 
Martinez et al report a pooled analysis of individual data from 8 prospective studies comprising 9167 
men and women aged 22 to 80 with previously resected colorectal adenomas to quantify their risk of 
developing subsequent advanced adenoma or cancer, as well as identify factors associated with the 
development of advanced colorectal neoplasms during surveillance.(17) Risk of new neoplasia at 
follow-up evaluation is estimated according to baseline adenoma characteristics. Data from the 
Martinez study was converted into annual transition probabilities assuming a follow-up period of 4 
years; see Table 3.1.7. It should be noted that the definitions of low and high risk used in the Martinez 
study differs slightly from the definitions used in the BSG surveillance guidelines; however, the 
Martinez study was still deemed to be the best available data source. 
 
Restrictions on transition probabilities post polypectomy
Post polypectomy(LR) to LR adenoma  > Normal epithelium to LR adenoma
Post polypectomy(HR) to LR adenoma  > Normal epithelium to LR adenoma 
Post polypectomy(LR) to HR adenoma  < LR adenoma to HR adenoma
                                                                         > Normal epithelium to HR adenoma
Post polypectomy(HR) to HR adenoma  > Normal epithelium to HR adenoma 
Post polypectomy(LR) to CRC  < LR adenoma to CRC 
                                                         > Normal epithelium to CRC
Post polypectomy(HR) to CRC  < HR adenoma to CRC
                                                         > Normal epithelium to CRC
Post polypectomy(LR) to LR adenoma< Post polypectomy(HR) to LR adenoma
Post polypectomy(LR) to HR adenoma< Post polypectomy(HR) to HR adenoma
Post polypectomy(LR) to CRC adenoma< Post polypectomy(HR) to CRC adenoma
Find
Surveillance 
undertaken in 2008 
assumed to be 1-year 
surveillance)
Surveillance 
(undertaken in 2010 
assumed to be mainly  
3-year surveillance)
Persons 
undergoing 3-
yearly surveillance
Persons 
undergoing 1-year 
surveillance
CRC 1.3% 0.3% 0.1% 1.3%
HR adenomas 55.7% 24.4% 9.1% 56.8%
LR adenomas 14.5% 31.9% 16.3% 18.8%
*Estimated annual recurrence rates w ere calculated by adjusting for the number of years until surveillance and colonoscopy miss rates.
Detection rates at surveillance Estimated annual reccurrence rate *
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Table 3.1.7: Data from Martinez et al 2009
 
 
The model uses recurrence rates from the English BCSP for persons with HR adenomas and data 
from Martinez et al for persons with LR adenomas. This data on recurrence rates post-polypectomy 
has several limitations. The transition probabilities reported are not age-dependent; however, the 
transition probabilities used in the model are age-dependent. The study populations do not reflect the 
English screening population, are quite small in size, do not use the BSG surveillance guidelines to 
categorise adenomas, and report highly varying recurrence rates. It is very important that detailed 
data on outcomes at surveillance in the English gFOBT screening programme is collected and 
available for future modelling work to improve the accuracy of decision support for the screening 
programmes. 
 
3.1.7 Classification of adenomas 
Adenomas can be categorised in the following ways: by size: <5mm, 5-10mm, 10-20mm, 20+mm and 
by type: tubulovillous/villous (>25% villous features), advanced/non-advanced, high grade dysplasia. 
In addition, persons can be classified by number of adenomas present or by BSG surveillance 
guidelines risk level: low/intermediate/high. 
 
The majority of the colonoscopy studies identified in the systematic review classify adenomas as 
advanced or non-advanced. As the definition of ³advanced DGHQRPD´ includes tubulovillous or villous 
adenomas, it will include some individuals who would be classified as low-risk according the BSG 
guidelines. There will also be some individuals with 3-4 small adenomas who are classified as 
intermediate risk according the BSG guidelines but who do not have advanced adenoma. Out of 
persons found to have an advanced adenoma in the FS trial, 74% were classified as intermediate or 
high risk according to the BSG guidelines. Hence it was assumed that 74% of persons with advanced 
adenoma had high-risk adenomas. 
 
Table 3.1.8: Classification of persons with adenomas
 
 
Data from the gFOBT screening programme in England reports detection rates of 
low/intermediate/high-risk adenomas (according the the BSG guidelines), and this classification is 
used to determine an individual¶s surveillance. Data from iFOBT screening in Italy and colonoscopy 
screening in Germany reports detection rates for ³advanced DGHQRPDV´. There is great value to be 
had in using all of these data sources, as they provide valuable information regarding the different 
screening modalities. The differences in the reporting of adenoma detection rates are problematic and 
Adenoma history*
Non advanced 
adenoma Advanced adenoma** Colorectal cancer
Non advanced 
adenoma
Advanced 
adenoma
Colorectal 
cancer
Low-risk 0.345  (0.331,0.358) 0.069  (0.062,0.076) 0.005  (0.003,0.007) 10.0% 1.8% 0.1%
High-risk 0.353  (0.339,0.367) 0.155  (0.145,0.166) 0.008  (0.005,0.01) 10.3% 4.1% 0.2%
**Advanced adenoma are defined as those w ith a diameter 10mm or larger, having greater than 25% villous 
features, or having high-grade dysplasia.
7KHORZ ULVNJURXSLQFOXGHVSDWLHQWVZ LWK±VPDOOFPWXEXODUDGHQRPDVZ LWKORZ JUDGHG\VSODVLD
The high-risk group includes patients w ith 3 or more d nomas, or any adenomas 1 cm or larger in size, or 
Risk of new neoplasia at follow-up evaluation (median duration of 
follow up 47.2 months)
Annual transition probabilities (assuming a 
follow-up of 4 years)
Definition used in Brenner et al.
low risk
intermediate 
risk high risk Advanced adenoma
low risk 
adenomas
high risk 
adenomas
1-2 small (<10mm) adenomas X X
3-4 small (<10mm) adenomas X X
large (<=10mm) adenoma X X X
5+ small (<10mm) adenomas X X
3+ adenomas at least one of which is >=10mm X X
high grade dysplasia X X
1-2 small (<10mm) tubulovillous or villous adenoma X X X
3-4 small (<10mm) tubulovillous or villous adenoma X X X
5+ small (<10mm) tubulovillous or villous adenoma X X X
BSG surveillence guidelines Model health states
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introduce great uncertainty into the modelling. An internationally consistent way of reporting adenoma 
findings from screening programmes and trials should be a priority for the future. 
 
3.1.8 Adenoma and CRC prevalence in an asymptomatic population 
Data on the prevalence of CRC and adenomas by age in a screening population (asymptomatic) was 
required to inform the CRC natural history model. Such data are available from autopsy studies and 
can also be estimated from colonoscopy screening studies. A systematic review of data from 
colonoscopy studies in an asymptomatic population and autopsy studies was undertaken. Studies 
which report adenoma detection/prevalence rates by age were identified. Full details of the systematic 
review are included in Appendix 1.  
 
Colonoscopy studies provide data on adenoma prevalence but as colonoscopy is not a perfect test 
some adenomas (in particular small adenomas) may be missed. Adenoma prevalence estimates from 
colonoscopy screening studies may also be biased as they consist of a population who attend 
screening which is likely to differ slightly to the general population. The systematic review identified 
eight colonoscopy studies which are described in Table 3.1.9; the largest of which described the 
results of over 2 million colonoscopies from the German screening programme. (18)  For the model 
calibration data the study by Brenner et al was selected due to the large sample sizes, broad age 
range, and the expected similarity between the German and English screening populations. To 
incorporate some data on LR adenomas (not reported by Brenner et al) and some information for 
persons aged under 60, data from Chung et al 2010 was also included. (19) Further discussion on the 
international variation in CRC and adenoma prevalence is included in a later section of this report. 
Figures 3.1.2 and 3.1.3 present data on advanced adenoma prevalence by age from colonoscopy 
studies identified by the systematic review.  
Table 3.1.9: Summary of colonoscopy study characteristics
 
 
adenoma 
>=1cm in 
size/diame
ter
adenoma 
containing villous 
features />= 25% 
villous features
adenoma 
with high 
grade 
dysplasia
 adenoma 
with 
malignant 
features
 adenoma 
with 
carcinoma 
in situ
Rundle et al (2008) 2004 - 2006 United States 905 40-59 Y Y Y
Lin et al (2006)  2002 - 2005 United States 1244 >= 50 Y Y
Strull et al (2006) 1996 - 2003 Israel 1177 40-80 Y Y Y
United States 3403 40-70
Taiwan 1456 40-70
Yamaji et al (2004)  1988 - 2002 Japan 4084 all ages Y Y Y
Chung et al (2010) 2004 - 2007 Korea 5254 30-59 Y Y Y
Brenner et al (2007) 2003 - 2004 Germany 840,149 50-80+ Y Y Y
Brenner et al (2010) 2003 - 2007 Germany 2,185,153 50-75 Y Y Y
Choe et al (2007) 1998 - 2004 Korea 5086 >=20 Y Y Y Y
Soon et al (2005)
Study
Data 
Collected 
(Time-
Interval)
Country of 
study
Sample 
Size Age Range
2002 - 2004
Included within study definition of advanced adenoma:
Y Y Y Y
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Figure 3.1.2: Advanced adenoma detection rates in colonoscopy studies identified by systematic 
review                                                                                       
 
 
Figure 3.1.3: Advanced adenoma detection rates in colonoscopy studies identified by systematic 
review                                                                               
 
Autopsy studies allow a complete and thorough examination of the colon and rectum; however, data 
from autopsy studies may be biased, as autopsied individuals represent a biased sample of deaths. In 
addition, autopsy studies do not always include an equal cross-section of ages. The systematic 
review identified X autopsy studies. Due to the large amount of heterogeneity in the autopsy studies 
and the small sample sizes when compared to colonoscopy studies, the autopsy study data was not 
used within the model calibration. 
 
3.1.9 Colorectal cancer incidence in the absence of screening by age and stage 
'DWDRQ&5&LQFLGHQFHLQWKHDEVHQFHRIVFUHHQLQJFDWHJRULVHGE\DJHDQG'XNHV¶VWDJHDW
diagnosis was taken from England cancer registry data for Oxford, Northern and Yorkshire, and 
Eastern regions from 2004 ± 2006.(20) 
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Figure 3.1.4: CRC incidence rates in the absence of screening by age and DXNH¶VWDJH 
 
 
3.1.10 Screening programme data 
Observed data from existing screening programmes and screening trials was used within the 
calibration of the model. The screening detection rates are essential to estimate the sensitivities of the 
screening tests while the false positive rates inform screening test specificity. Note that we define the 
false positive rate to be the proportion of persons undergoing colonoscopy following FOBT in whom 
no CRC or adenomas were found at colonoscopy. The change in screening positivity and detection 
rates by age provide important information for the natural history model, i.e. the change in underlying 
adenoma and CRC prevalence by age.  
 
Table 3.1.9 provides a summary of the screening data used within the model calibration. The current 
gFOBT BCSP in England  reported numbers of persons with positive gFOBT result and the detection 
rates of low and high risk adenomas and CRC at screening.(21) Data from the FS trial consisted of 
detection rates of CRC, low/high risk adenomas and non-advanced/advanced adenomas at 
screening.(5)  As UK data is only available for the gFOBT and FS, screening test data from Italy was 
used for iFOBT screening.  
 
The population of the FS trial differed slightly from a screening population, as all persons had 
indicated that they were interested in attending screening in the questionnaire. The screening data 
used in the calibration relates to persons who attended screening. Screening attenders in the FS trial 
may be slightly healthier than those undergoing gFOBT screening, hence they may have slightly 
lower detection rates at FS screening  leading to a slightly lower estimate of FS sensitivity, thus 
biasing the result slightly in the favour of FOBT. This slight difference between the screening 
populations is not expected to significantly bias the model results. In fact, an analysis demonstrated 
that the FS trial control population had lower mortality rates than Norwegian control but incidence was 
the same. 
 
Colonscopy screening is not considered in this evaluation; however, data from screening 
colonoscopies is of particular use for calibrating the model because of the accuracy of colonoscopy. 
As mentioned earlier, colonoscopy screening data was used in preference to autopsy study data as 
the sample sizes are much larger. 
 
Figures X to Y present the screening data which was used within the calibration process. The higher 
detection rates seen at FS screening indicate that FS is much more sensitive than gFOBT. 
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Table 3.1.9: Screening data used within model calibration 
 
 
 
Figure 3.1.5: CRC and adenoma detection rates at screening and FOBT false positive rates with 95% 
confidence intervals presented as vertical lines
 
  
 
3.1.11 International variation in CRC and adenoma prevalence 
There exists data describing the international differences in the incidence of CRC, however, there is 
little evidence describing the difference in the prevalence of CRC and adenomas. Soon et al 
undertook a study in which a cohort of patients in both Taiwan and Seattle received colonoscopy. 
7KH\FRQFOXGHGWKDW³FRPSDUHGWR:HVWHUQHUV&KLQHVHSDWLents have a slightly lower prevalence of 
Screening 
test Source Country
Time period 
screening 
undertaken
Number of 
particpants 
undergoing 
screening
Age range of 
participants Data reported
gFOBT England BCSP England 2006-2010  2,889,925 59-74
false positive rate; detection rates for LR adenomas, 
HR adenomas and CRC
iFOBT Zorzi et al Italy 2006-2010     591,152 50-69
false positive rate; detection rates for non-advanced 
adenomas, advanced adenomas and CRC
FS Atkin et al England 2005-2008       40,621 55-65
detection rates for LR adenomas, HR adenomas and 
CRC
Colonoscopy Brenner et al Germany 2003-2007  2,185,153 55-75 detection rates for advanced adenomas and CRC
Colonoscopy Brenner et al Germany 2003-2004     840,149 50-80+ detection rates for advanced adenomas
Colonoscopy Chung et al 2003-2007        5,254 30-59
detection rates non-advanced adenomas, advanced 
adenomas and CRC
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colon neoplasia (but not advanced neoplasia), more distal distribution of neoplasia, and higher 
likelihood of concomitant SUR[LPDODGYDQFHGQHRSODVLDDQGGLVWDOQHRSODVLD´ (22) 
 
Differences in adenoma and CRC prevalence between England, Germany and Italy may exist; 
however, the extent of these differences is unknown. The value of using data from more than one 
country is that it allows the use of large datasets from several different screening modalities. The 
benefit of including data on different screening modalities was considered to outweigh the uncertainty 
introduced by using datasets from different countries. 
 
 
3.1.12 Mortality rates 
CRC 1, 3 and 5 years relative survival by stage at diagnosis were taken from England cancer registry 
data of diagnoses between 1997 and 2001.(20)  As a significant proportion of patients survive 
colorectal cancer (5 year relative survival is over 90% for Dukes A), it is not appropriate to use a 
FRQVWDQWPRUWDOLW\UDWHH[SRQHQWLDOPRGHO)RUHDFK'XNHV¶VWDJHDPL[HGPRGHOZDVXVHGIRU&5&
mortality which assumes that a certain proportion of patients will be cancer survivors.  
 
Other-cause mortality was taken from ONS life tables based on data for the years 2007-2009 with 
CRC death removed.(23) 
 
Figure 3.1.6: CRC survival by stage and time from diagnosis 
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3.2 Natural history model calibration method 
Model calibration used the methods described by Whyte et al, and figures describing the method are 
included in  Appendix 2.(4) For a given parameter set, the model can be run to produce predictions of 
CRC incidence, adenoma prevalence and screening outcomes. The aim of the calibration is to obtain 
parameter sets whose predictions are close to the observed data. For each data set, the sum squared 
error (SSE) was calculated by comparing the observed number of observations to the predicted 
number of observations for each age. The total SSE is a measure of how well the model fits to all the 
observed data sets. The aim of the calibration is to obtain multiple parameter sets which each 
produces a model that has a good fit to the observed data sets (determined by consideration of total 
SSE). 
 
The Metropolis Hastings (MH) algorithm was used for the calibration process to generate multiple sets 
of parameters.(24) These parameter sets form the posterior distribution which is compatible with the 
observed data, accurately representing parameter uncertainty.  This approach embeds the problem in 
the framework of Bayesian inference and produces correlated parameter sets which can be used for 
probabilistic sensitivity analyses (PSA). Correct representation of the joint uncertainty in these 
parameters is particularly important because of the potential for correlation between several of these 
parameters.  
 
The model calibration was run eight times using different sets (randomly generated) of initial 
parameter values to ensure that the best fitting parameter set was obtained.  Each run consisted of 
50,000 iterations of the MH algorithm and could be run overnight on a standard PC. A sample of 250 
parameter sets from after convergence from four of the runs were combined to form 1000 parameters 
sets to be used to run the PSA. 
 
A large number of parameters was being estimated within the calibration process, which can lead to 
low acceptance rates and slow convergence. Hence an approach was implemented in which there 
was a random 30% probability that a given parameter was varied on each run, and this increased 
acceptance rates and time to convergence. 
 
 
3.3 Model calibration results 
 
Figures 3.3.1-3.3.2 show the model predictions compared to the observed data for the best fitting 
parameter set resulting from the calibration process. The model obtained a good fit to the observed 
data on CRC incidence in the absence of screening and to the data on gFOBT, iFOBT and FS 
screening.  
 
The best fitting parameter set and 95% percentiles are presented in Table 3.3.1. The 95% percentiles 
demonstrate that there are varying degrees of uncertainty surrounding the different parameter values. 
For example, there is considerable uncertainty surrounding the FS CRC sensitivity value, as the 
sample sizes are quite small for the CRC detection rates at FS screening.  We note that although the 
CRC sensitivity estimates for FS and iFOBT were similar, FS has higher detection rates because it is 
associated with a higher rate of compliance with follow-up colonoscopy.  
 
The correlation matrix for all the parameters estimated within the calibration process is included in 
Appendix 2, and this demonstrates the importance of including between-parameter correlation within 
the modelling.  
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Figure 3.3.1: Model predictions compared to observed data for CRC incidence in the absence of 
screening                
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Figure 3.3.2: Model predictions compared to observed data for detection rates at gFOBT, iFOBT, 
flexible sigmoidoscopy and colonoscopy screen
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Table 3.3.1: Model calibration results: best fitting parameter set and 95% percentiles 
 
  
  
Parameter
Maximum a posteriori estimate,    
(95% percentiles) 
Annual transition probabilities
Normal epithelium to LR adenomas - age 30   0.021     (0.020, 0.022)
Normal epithelium to LR adenomas - age 50   0.020     (0.019, 0.021)
Normal epithelium to LR adenomas - age 70   0.045     (0.029, 0.047)
Normal epithelium to LR adenomas - age 100   0.011     (0.005, 0.031)
LR adenomas to high risk adenomas - age 30   0.009     (0.007, 0.014)
LR adenomas to high risk adenomas - age 50   0.008     (0.006, 0.008)
LR adenomas to high risk adenomas - age 70   0.008     (0.008, 0.010)
LR adenomas to HR adenomas - age 100   0.004     (0.003, 0.010)
HR adenomas to Dukes A CRC - age 30   0.029     (0.004, 0.031)
HR adenomas to Dukes A CRC - age 50   0.025     (0.022, 0.026)
HR adenomas to Dukes A CRC - age 70   0.054     (0.050, 0.058)
HR adenomas to Dukes A CRC - age 100   0.115     (0.084, 0.118)
Normal epithelium to CRC Dukes A   0.00004     (0.00003, 0.00008)
Preclinical CRC: Dukes A to Dukes B   0.51     (0.50, 0.89)
Preclinical CRC: Dukes B to Dukes' C   0.69     (0.50, 0.70)
Preclinical CRC: Dukes C to Stage D   0.71     (0.59, 0.73)
Symptomatic presention with CRC Dukes A   0.04     (0.04, 0.07)
Symptomatic presention with CRC Dukes B   0.18     (0.12, 0.18)
Symptomatic presention with CRC Dukes C   0.37     (0.30, 0.39)
Symptomatic presention with CRC Dukes D   0.74     (0.65, 0.92)
Screening test characteristics
gFOBT Sensitivity for LR adenomas   0.009     (0.009, 0.010)
gFOBT Sensitivity for HR adenomas   0.124     (0.121, 0.125)
gFOBT Sensitivity for CRC   0.242     (0.233, 0.253)
gFOBT Specificity age 50   0.994     (0.991, 0.995)
gFOBT Specificity age 70   0.973     (0.972, 0.978)
FS Sensitivity for LR adenomas   0.219     (0.212, 0.229)
FS Sensitivity for HR adenomas   0.710     (0.685, 0.742)
FS Sensitivity for CRC   0.617     (0.612, 0.741)
iFOBT Sensitivity for LR adenomas   0.045     (0.043, 0.047)
iFOBT Sensitivity for HR adenomas   0.322     (0.315, 0.332)
iFOBT Sensitivity for CRC   0.629     (0.606, 0.646)
iFOBT Specificity age 50   0.975     (0.971, 0.977)
iFOBT Specificity age 70   0.925     (0.920, 0.937)
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3.4 Model validation 
The model was validated by comparing model predictions to screening data which was not used in 
the calibration process. This data consisted of results from repeat screens in the FOBT screening 
programmes and changes in incidence and mortality in the 11 year period following FS screening. 
 
Model predictions of changes to CRC incidence and mortality following a FS screen were compared 
to those seen in the FS trial. The FS trial reports that in persons attending screening, CRC incidence 
was reduced by 33% (HR 0·67, 95% CI 0·60±0·76) and CRC mortality by 43% (HR 0·57, 95% CI 
0·45±0·72) in the follow-up period (median 11.2 years).(6) Considering a follow-up period of 11 years, 
the model predicts that CRC incidence will be reduced by 29% (HR=0.71) and mortality by 34% 
(HR=0.66) for persons receiving a FS screen at ages 55-64. These hazard ratios are within the 
confidence intervals reported by the FS trial. 
 
Data from persons undergoing repeat screens with iFOBT in Italy provides details of positivity and 
detection rates and is presented in Figure 3.4.1.(25) The data demonstrates a significant decrease in 
positivity and detection rates at the repeat screen with a more marked difference in the older ages. In 
this data set, ³repeat screens´ includes persons undergoing their second or third screen. As specific 
data on the second iFOBT screen was not available, this data was not suitable for validation. 
 
Figure 3.4.1: Positivity and detection rates and initial and repeat iFOBT screen in the Italian screening 
programme 
 
 
 
Figure 3.4.2 presents data on persons undergoing a second gFOBT in the NHS BCSP that was used 
for model validation. The comparison between gFOBT second screen data and the model prediction 
is presented in Figure 3.4.3. This demonstrates that the model produces a good fit to CRC detection 
rate for the second screen data. Surprisingly, the data shows a small increase in the LR adenoma 
detection rate between the first and second screens. It is suspected that this may be due to 
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
10%
50 55 60 65 70
iFOBT Positivity rate
Subjects at first exam Subjects at repeated exam
0.0%
0.2%
0.4%
0.6%
0.8%
1.0%
50 55 60 65 70
iFOBT CRC detection rate
Subjects at first exam Subjects at repeated exam
0.0%
0.5%
1.0%
1.5%
2.0%
50 55 60 65 70
iFOBT Advanced adenoma detection rate
Subjects at first exam Subjects at repeated exam
0.0%
0.5%
1.0%
1.5%
2.0%
50 55 60 65 70
iFOBT Non-advanced adenoma detection rate
Subjects at first exam Subjects at repeated exam
 27 
 
improvements in colonoscopy quality between the first and repeat screens. The data shows a marked 
decrease in HR adenoma detection rates which is much larger than the decrease predicted by the 
model. There is also a much higher false positive rate seen at the second screen; however, the model 
predicts that specificity will not vary by number of screens. 
  
The difference between the gFOBT second screen data and the model predictions suggests that: (1) 
the second screen data is in some way biased, or (2) gFOBT sensitivity and specificity vary by 
first/repeat screen which is not represented by our model structure. Possible sources of bias effecting 
the gFOBT first/second screen data are not well understood. Lower detection rates and higher false 
positive rates at a second/repeat screen would result in a strategy of repeated gFOBT being 
significantly less effective than is predicted by this model. This issue results in significant uncertainty 
surrounding the efficacy of the use of gFOBT for repeated screens.  
 
Figure 3.4.2: Positivity and detection rates at initial and second gFOBT screens in the NHS BCSP 
(showing 95% CIs)                                  
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Figure 3.4.3: Model predictions compared to observed data for second gFOBT screens in the NHS 
BCSP                                                         
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3.5 Model parameter values 
3.5.1 Modelling assumptions 
The modelling approach and data sources follow the NICE guidelines for technology appraisal. (26) 
Costs and QALYs will be discounted by 3.5%. To allow a fair comparison between screening 
interventions which commence at different ages, discounting will start at age 50, which is earlier than 
the age at which screening intervention is first offered. A willingness-to-pay threshold of £20,000 is 
used. 
 
3.5.2 Cost of screening programme 
The costs associated with the various components of a screening programme were estimated using a 
cost model for the Southern screening hub. There is likely to be some variation in costs between 
hubs, but the scale of these variations is uncertain. The Southern hub cost model includes estimates 
of staff costs, consumables, capital purchases and overheads.  
 
Details of the costs used, data sources and assumptions made are provided in Table 3.5.1. 
The cost of letters sent out includes cost of consumables, fulfilment (packing), postage, staff costs, 
capital costs and overheads. The costs associated with the following letters involved in the gFOBT 
screening process were estimated: invitation letter (subject), kit letter and leaflets (subject), reminder 
letter (subject), retests (subject), normal FOBT letter (subject and GP), non-attendance letters(GP) 
and positive FOBT letters (subject and GP). The other components of screening programme costs 
estimated were: return postage for test kits, dealing with kits returned ³not known at this DGGUHVV´, 
helpline, laboratory for processing test kits, booking appointments for subjects with positive FOBT. 
In order to estimate the costs associated with an iFOBT or FS screening programme, several 
assumptions were made.  
 
The cost of sending out an iFOBT kit was assumed to include the cost of posting a packet weighing 
less than 100g second class with Royal Mail; the cost of packaging and fulfilment (estimated by 
Stephen Halloran); and staff costs and overheads at the same rate as was incurred for sending out 
the gFOBT kit. The return postage costs for an iFOBT kit were assumed to be the cost of posting a 
packet weighing less than 100g first class with Royal Mail. Estimates of iFOBT processing costs 
include predicted laboratory staff requirements for the Southern hub; the cost of instrument rental is 
assumed to be £0, and the cost of instrument maintenance is assumed to be £100,000 per annum for 
five instruments. The number of letters sent out for iFOBT screening was assumed to be the same as 
for gFOBT screening. The proportion of persons phoning the helpline was assumed to be the same 
as for gFOBT. 
 
FS screening was assumed to involve the following steps: pre-invitation letter sent to subject, 
scannable health questionnaire sent to subject, letter with FS appointment time (sent to subject 
suitable for screening), appointment confirmed via automated telephone service, consent form sent to 
subject, bowel preparation sent to subject, individuals with uncertain fitness for FS contact SSP. 
7KHUHPD\EH1+6,7LVVXHVZLWKWKHLPPHGLDWHLPSOHPHQWDWLRQRIWKH³VFDQQDEOHKHDOWK
questionnaire and appointment conILUPHGYLDDXWRPDWHGWHOHSKRQHVHUYLFH´, but it is assumed that in 
the long term this approach would be used. Each of the letters sent was assumed to cost the same as 
the gFOBT invitation letter. The BNF price for a Fleet enema was assumed, and postage of the 
enema was assumed to be the cost of posting a packet weighing less than 100g second class with 
Royal Mail, signed for. However, as a bulk purchase of enemas would be required, it is likely that a 
price lower than the BNF price could be achieved in practice. Fulfillment and overhead costs for 
sending out of enemas were assumed to be the same as for sending out FOBT kits. The proportion of 
persons phoning the helpline with queries relating to FS screening was assumed to be 40% higher 
than for that seen with FOBT screening. 
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Table 3.5.1: Screening Costs 
 
Cost Source
gFOBT kit (includes device, spatula, envelope, 
and reagents) 0.46£      National contract cost
gFOBT kit consumables, fulfillment, postage 0.38£      
Southern hub cost estimates: postage 0.192, fulfillment 0.072, 
consumables 0.059, staff costs and overheads 0.05
gFOBT return postage 0.35£      Royal mail business reply plus
gFOBT processing costs (per test) 0.78£      Southern hub cost estimates
iFOBT kit 2.50£      
Stephen Halloran (note: Northern Italy currently pay 1 euro, a 
lower cost is considered in a SA)
iFOBT kit postage 2.74£      
Postage 2nd class packet<100g £1.17, packaging costs of 
£0.25, fulfillment of £0.10, staff costs and overheads 0.05
iFOBT return postage 1.17£      Royal mail 1st class packet <100g £1.39
iFOBT processing costs (per test) 0.64£      Southern hub cost estimates
Bowel preparation for FS 0.57£      
BNF cost for Fleet® Ready-to-use Enema (Casen-Fleet) 
Enema £0.57 133-mL pack (delivers 118 mL dose) with 
standard tube
Bowel prep for FS postage, packaging and 
fulfillment 2.32£      
 Postage 2nd class packet<100g £1.17+ for signed for £0.75, 
packaging £0.25, fulfillment £0.10, staff costs and overheads 
0.05 
Repeat test costs
gFOBT Retest costs (kit and processing) 3.19£      
Additional cost of hub sending out retests via royal mail is 
£1.22
gFOBT Retest rate 0.08        Southern hub data and gFOBT pilot data
gFOBT Retest costs per screening completer 0.25£      Calculated from above
iFOBT Retest costs (kit and processing) 9.49£      
Additional cost of hub sending out retests via royal mail is 
assumed to be 2x£1.22 due to additional packaging and 
storage costs
iFOBT Retest rate
0.03        
Retesting will be required if test is not returned within 7/10 
days, approximately 97% of gFOBTs are returned within 7 
days, 95% within 5 days
iFOBT Retest costs per screening completer 0.28£      Calculated from above
FS repeat test rate
Invitation letter 0.34£      Southern hub cost estimates
Reminder letter 0.34£      Southern hub cost estimates
Reminder letter cost per invitee 0.17£      Calculated from above
Non-attender letter to GP 0.14£      Southern hub cost estimates
Normal result letter to subject and GP 0.45£      Southern hub cost estimates
Positive result letter to subject and GP 3.74£      Southern hub cost estimates
Helpline costs
Helpline costs per call 2.83£      Southern hub cost estimates
gFOBT Proportion of those invited calling 
helpline 0.19        Southern hub cost estimates
gFOBT Helpline costs per screening invitee 0.53£      Calculated from above
iFOBT Proportion of those invited calling 
helpline 0.19        Assume helpline call frequency same for gFOBT and iFOBT
iFOBT Helpline costs per screening invitee 0.53£      Calculated from above
FS Proportion of those invited calling helpline 0.40        
Estimate by Stephen Halloran (to include persons with 
uncertain fitness for FS talking to a SSP)
FS Helpline costs per screening invitee 1.13£      Calculated from above
Appointments for follow up for positives 5.53£      Southern hub cost estimates
Flexible Sigmoidoscopy Examination Alone 186£       NHS reference costs 2003 (inflated)
Flexible Sigmoidoscopy with Biopsy or Therapy 195£       NHS reference costs 2003 (inflated)
Colonoscopy Examination Alone 205£       NHS reference costs 2003 (inflated)
Colonoscopy with Biopsy or Therapy 237£       NHS reference costs 2003 (inflated)
Cost of pathology 27£         
Test costs, return test postage, test processing costs
/HWWHUFRVWVLQFOXGLQJFRQVXPDEOHVIXOILOOPHQWSRVWDJHVWDIIFRVWVRYHUKHDGV«
Endoscopy costs
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A summary of costs of screening (excluding the costs of follow up colonoscopy) are provided in table 
3.5.2. 
Table 3.5.2: Costs of screening - summary 
 
 
 
3.5.3 Cost of colonoscopy and flexible sigmoidoscopy 
An appointment with a specialised screening practitioner (SSP) nurse is required before a patient 
receives a follow up colonoscopy. Based on clinical opinion we assume that this will incur 30 minutes 
nurse time for referral to colonoscopy from FOBT and 15 minutes nurse time for referral to COL from 
FS screen. For FS the appointment may either take place immediately following their exam before 
they leave the clinic, or be arranged by telephone once pathology results are in. The cost of SSP 
nurse time is assumed to be the cost of a specialist nurse (community) of £36 per hour taken from the 
Unit costs of health and social care 2009. (27)  
 
Evidence on the cost of colonoscopy and flexible sigmoidoscopy is available in the 2003 and 2005 
NHS reference costs (more recent NHS reference costs unfortunately do not include costs which 
relate specifically to these procedures) and in a paper by Whynes et al. (28-30) The reference costs 
were inflated to 2008/2009 values using inflation indices reported in the Unit costs of health and social 
care 2009. (27)  In addition an estimate of costs has been provided by Derbyshire Screening Centre 
and these costs include staff, procedure and pathology costs. (31) A cost estimate for colonoscopy 
(including specialised screening practitioner, imaging and pathology costs) was provided by 
Chesterfield Royal Hospital NHS Foundation Trust.(32) 
 
Table 3.5.3: Endoscopy costs 
 
 
 
Summary screening costs Cost
gFOBT screening
Non attender 2.03£      
Normal test result 3.36£      
Positive test result 11.94£     
iFOBT screening
Non attender 6.43£      
Normal 7.37£      
Positive 16.20£     
Flexible Sigmoidoscopy screening
Non attender 5.02£      
Normal 6.01£      Note this cost excludes the cost of flexible sigmoidoscopy
Positive 14.84£     Note this cost excludes the cost of flexible sigmoidoscopy
Procedure
Published 
cost Source
 Inflated to 
2008/2009 
Colonoscopy £347 2005 Reference Costs £401
Colonoscopy with Biopsy or Therapy £198 2003 Reference costs * £237
Colonoscopy Examination Alone £172 2003 Reference costs * £205
Colonoscopy, incl. pathology £245 Derbyshire BCSP £245
Colonoscopy including SSP, imaging, pathology £550 Chesterfield Royal Hospital 
NHS Foundation Trust
£550
Flexible Sigmoidoscopy £275 2005 Reference Costs £318
Flexible Sigmoidoscopy with Biopsy or Therapy £164 2003 Reference costs * £195
Flexible Sigmoidoscopy Examination Alone £156 2003 Reference costs * £186
Flexible Sigmoidoscopy £56 Whynes 2003 £80
Flexible Sigmoidoscopy, nurse led, incl pathology £101 Derbyshire BCSP £101
*Average of procedures w ith surgical and medical gastroenterology HRG labels
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The cost of FS will vary considerably depending on whether it is nurse-led or consultant-led. The 
proportion of FS procedures which are likely to be nurse-led in a screening programme situation is 
unknown.  
 
The ratio of the cost of a FS procedure to a colonoscopy procedure is unknown. In a third sensitivity 
analysis, a greater difference between the cost of FS and colonoscopy is considered based on the 
costs estimates from the Derbyshire screening programme. This analysis is consistent with the 
suggestion that the number of procedures completed per session is 10-12 for flexible sigmoidoscopy 
compared to 4-6 per session for colonoscopy. (5) 
 
The 2003 values have been used in the base case analysis as they distinguish between procedures 
with and without polypectomy.  The differences between the 2003 and 2005 reference cost values 
and the estimate from Whynes et al demonstrate that there is considerable uncertainty surrounding 
endoscopy costs. Sensitivity analyses on the endoscopy costs were undertaken. The first sensitivity 
analysis uses the values reported in 2003 multiplied by a factor of 1.7 to reflect the values in the 2005 
reference costs, whilst still distinguishing between with/without polypectomy.  The second sensitivity 
analysis will consider lower values for endoscopy costs (50% of base case cost estimates) to reflect 
the fact that costs in a population screening situation may be lower than those reported in the NHS 
reference costs. A third one-way sensitivity analysis reflects the likely reduced cost of nurse-led 
flexible sigmoidoscopy with values derived from the Derbyshire screening centre estimates.  
 
Table 3.5.4: Endoscopy costs used in model 
 
 
Polypectomy will always involve a biopsy. Unfortunately it is unclear whether the NHS reference costs 
for endoscopy include the pathology costs associated with biopsy. For the purposes of this analysis 
we assume that pathology cost will be incurred on top of the procedure costs. The Derbyshire 
screening programme estimates average pathology costs of £50 for FS and £72 for colonoscopy. The 
NHS reference cost for histopathology is £26 and this cost has been used in the model for both 
cancer and adenoma. The mean number of adenomas requiring pathology was assumed to be 1.9 
based on data reported from the National Polyp Study by Winawer et al.(33) Wendy Atkin is 
proposing the introduction of a ³National/regional pathology processing FHQWUH´ which would aim to 
reduce pathology costs while at the same time increasing standardisation.  To reflect this possibility a 
one-way sensitivity analysis on pathology costs (+/- 20%) was performed.  
 
3.5.4 Complications following endoscopy 
Colonoscopy and flexible sigmoidoscopy procedures are associated with a small risk of bleeding or 
perforation; and perforation may lead to death. Incidence of bleeding, hospitalisation for bleeding and 
perforation following flexible sigmoidoscopy and colonoscopy procedures with and without perforation 
are taken from the flexible sigmoidoscopy trial.  There were no perforations following colonoscopy or 
flexible sigmoidoscopy without perforation, so the perforation rate was assumed to be 0%. Data on 
perforation rates for colonoscopy following a positive FOBT was also taken for the FS trial, as data 
from the BCSP was suspected to be inaccurate due to incomplete reporting. 
 
Gatto et al report that the incidence of death subsequent to a perforation within 14 days of a 
procedure was 4 out of 77 colonoscopic perforations (5.2%) and 2 out of 31 sigmoidoscopic 
perforations (6.5%). This study refers to a Medicare population, so the cases may be older and in 
worse health than the proposed English screening population; however, no alternative reference was 
Procedure
Base case 
estimate
Low values 
for SA
High values 
for SA
Values for 
3rd SA
Colonoscopy with Biopsy or Therapy £237 £118 £402 £269
Colonoscopy Examination Alone £205 £103 £349 £245
Flexible Sigmoidoscopy with Biopsy or Therapy £195 £98 £332 £111
Flexible Sigmoidoscopy Examination Alone £186 £93 £316 £101
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identified. Gatto et al also reported that the risk of perforation from FS increased in association with 
increasing age, but this association has not been modelled here.(34) 
 
Table 3.5.5: Number of persons with bleeding, hospitalisation for bleeding and perforations in the FS 
trial 
 
 
 
Endoscopy complication rates are available for other countries. Rabeneck et al report a 
hospitalisation for bleeding rate of 0.14% and a perforation rate of 0.06% from over 90,000 
colonoscopies undertaken in Canada.(35)  Although the data from the FS trial is a much smaller 
dataset, we have chosen to use it here as it is specific to the UK setting. 
 
3.5.5 Cost of treating screening complications 
The cost of treating a perforation due to flexible sigmoidoscopy or colonoscopy was assumed to be 
£2164 (Major therapeutic open or endoscopic procedures, 19 years and over with major colon cancer 
major surgery).(36) The cost of treating hospitalised bleeding following flexible sigmoidoscopy or 
colonoscopy was assumed to be £262 (Very major procedure for gastrointestinal bleed). (36) 
 
The cost of treating a gastrointestinal bleed ranges from £350 to £407 (Non-Elective inpatient short 
stay HRG data HRGFZ38D, FZ38E, FZ38F) depending on length of stay and complication, hence a 
cost of £380 is assumed here. 
 
3.5.6 Colonoscopy test characteristics 
A systematic review of studies of tandem colonoscopies was undertaken by Van Rijn et al. (37) For 
adenomas of size <10mm 167 out of 711 were missed, and for adenomas of size >10mm 2 out of 96 
were missed. A study by Bressler et al estimated that out of 12496 cases of CRC, 430 were missed at 
colonoscopy (2%).(38) Based on these studies, sensitivity to low risk adenomas was assumed to be 
77%, sensitivity to high risk adenomas or CRC 98%, and specificity was assumed to be 100%. 
 
3.5.7 Screening test characteristics 
A systematic review of the diagnostic accuracy of FOBTs identified thirty-three studies that evaluated 
guaiac FOBTs.(39, 40)  Sensitivities for the detection of all neoplasms ranged from 6.2% (specificity 
98.0%) to 83.3% (specificity 98.4%) for guaiac FOBTs. Specificity ranged from 65.0% (sensitivity 
44.1%) to 99.0% (sensitivity 19.3%) for guaiac FOBTs.  The wide range in sensitivity values may be 
attributed to a number of factors including: study design, study populations, whether the test was 
rehydrated, test processing, and the choice of reference standard and test threshold. The substantial 
between-study heterogeneity makes performing a meta-analysis difficult.   
 
A systematic review and meta-analysis was undertaken to obtain estimates for the test characteristics 
of immunochemical faecal occult blood tests (iFOBT).  More specifically, this assessment updates and 
extends the systematic review conducted by Burch et al.,(39) which included studies up to November 
2004.  As the iFOBT Evaluation Report produced by the Centre for Evidence-based Purchasing 
concluded that the OC-Sensor/DIANA analyser was the most suitable system for the English BCSP, 
Procedure Number
FS with polypectomy 9499 29 0.31% 8 0.08% 1 0.011%
FS without polypectomy 31122 48 0.15% 4 0.01% 0 -      
FS 40621 77 0.19% 12 0.03% 1 0.002%
COL with polypectomy 1431 9 0.63% 6 0.42% 4 0.280%
COL without polypectomy 616 0 -      1 0.16% 0 -      
COL 2047 9 0.44% 7 0.34% 4 0.195%
PerforationBleeding
Hospitalisation 
for bleeding
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the review was limited to the OC-Sensor test. Full details of the search strategy and studies found are 
provided in Appendix 3. 
 
Several limitations of the results of the meta-analysis were identified: 
 Very poor reporting of the cut-off threshold used by the studies  
 The test characteristic estimates produced were surrounded by considerable uncertainty 
 Differences in test characteristic estimates between a trial and a screening setting 
This led to concerns over using the results of the meta-analysis within the modelling. Hence data from 
the existing Italian iFOBT screening programme was incorporated within the model calibration 
process to provide estimates of the sensitivity and specificity of iFOBT.  
 
In this study, sensitivity and specificity of the FS and FOBT screening tests will be estimated within 
the model calibration process. This approach combines observational data from screening with a 
natural history and screening model to estimate test characteristics.(41) FOBTs may identify 
conditions other than CRC and adenomas, and such conditions are likely to be more prevalent in an 
older population. Hence it follows that the number of persons with a positive FOBT result without 
CRC/adenomas increases with age, and this was observed in the data sets. In the modelling a 
specificity value which varied by age (linearly) was used.  
 
Data from Castiglione et al reports positivity and detection rates for iFOBT thresholds from 100-200 
for 11,774 persons aged 50-70 receiving their first screen as part of the Italian screening programme. 
(42) This data does not report detection rates by age so could not be used within the model 
calibration. This study also uses a slightly different definition of HR adenomas to that which reflects 
the BSG guidelines, gFOBT data, and the model structure. This data has been used to estimate the 
changes to iFOBT test characteristics associated with increasing the test threshold to 150 or 
200ng/ml. These values will be used in a sensitivity analysis. 
 
Table 3.5.6: iFOBT test characteristic estimates by referral threshold 
 
 
 
3.5.8 Test completion rates 
The bowel cancer screening pilot 2nd round evaluation reports that 5% of initial FOBTs have 1-4 
positive spots (weak positive) so require repeat testing per the NHS BCSP referral algorithm.(7) The 
evaluation of the 2nd round of the screening pilot reported that 66,264 gFOBTs were completed in 
phase 1, 2,972 in phase 2 and 2,236 in phase 3, hence the mean number of tests completed per 
person was 1.08. 
iFOBT threshold, ng/ml 100 150 200
Data from Castiglione et al 2002
Positivity rate 4.20% 3.00% 2.40%
CRC detection rate 0.33% 0.30% 0.27%
Highr risk* adenoma detection rate 0.79% 0.68% 0.59%
Low risk adenoma detection rate 0.26% 0.18% 0.12%
False positive rate 2.82% 1.84% 1.42%
Adjusted estimates of iFOBT test characteristics
iFOBT sensitivity to CRC 0.63       0.57       0.51       
iFOBT sensitivity to high risk adenomas 0.32       0.28       0.24       
iFOBT sensitivity to low risk adenomas 0.05       0.03       0.02       
iFOBT specificity age 50 0.975     0.984     0.992     
iFOBT specificity age 70 0.925     0.951     0.975     
*HR adenomas (definition used by Castiglione et al) - subjects w ith more than tw o adenomas or w ith 
severe dysplasia or w ith a villous or tubulovillous pattern. We note that this is not preceisley the 
definition of high risk used w ithin the model.
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Repeat testing will be required for iFOBT kits which are not returned within a certain period. The 
period of time in which a test must be returned is unclear, but we assume that a test must be returned 
within 7/10 days. Approximately 97% of gFOBTs are returned within 7 days and 95% within 5 days, 
hence the retest rate for iFOBT was assumed to be 3%. The Italian screening programme reported 
that 0.6% of persons had an inadequate test (due to incorrect sampling by the subject). (43) 
 
The FS screening trial reported that out of 40621 examinations undertaken, 2145 (5%) required 
repeating, and out of these1306 (3%) were repeated on the same day and 839 (2%) were repeated 
on a later day.  It was assumed that FS examinations repeated on the same day incurred no 
additional costs, and that if the examination was repeated on a later day then the cost of an additional 
FS examination would be incurred. 
 
Out of a total of 32,213 follow up colonoscopies undertaken from Aug 2006 to Aug 2008 in the NHS 
BCSP, in 1,481 (4.6%) the caecum was not reached, which could be due to pathology encountered, 
inadequate bowel preparation or patient discomfort. One can assume that majority of the 1,481 will 
have required a subsequent test which would usually be undertaken on a later day.(44) Persons 
requiring a subsequent test will receive a colonoscopy, a CT colonoscopy or a barium enema. Data 
from the NHS BCSP reports that out of 78,311 colonoscopy examinations, 5453 people (7%) who 
return within an episode to have another procedure which could be to remove more adenomas, to 
complete an incomplete test, or to check an adenoma removal site. Hence a repeat colonoscopy rate 
of 7% is assumed here.  
 
A summary of the repeat test rates used in the model is included within Table 3.5.7. 
 
 
 
Table 3.5.7: Repeat test rates 
Test  Rate  Source 
gFOBT mean number of tests 
completed 
        
1.08  
Bowel cancer screening pilot 2nd round evaluation, 
Table 5.2 
iFOBT mean number of tests 
completed 
        
1.01  
Asumption based on number of gFOBTs returned 
within 7 days, and data from Italian screening 
programme Zorzi et al 2009 
FS Probability test repeated on a later 
day 
        
0.02  
FS UK screening trial data, Atkin et al 2002 
COL repeat test rate         
0.07  
Data from gFOBT BCSP 
 
 
 
3.5.9 Lifetime costs of treating CRC 
$UHSRUWHQWLWOHG³7KH&RVWVDQG%HQHILWVRI%RZHO&DQFHU6HUYLFHV´TXDQWLILHGWKHDFWLYLWLHVFRVWV
and outcomes, associated with the treatment of bowel cancer.(45)  Costs for treating CRC, which are 
dependent on cancer stage at diagnosis, were taken from this report and inflated to give values for 
2010 using the inflation indices reported in the Unit costs of health and social care 2009.(27) It was 
assumed that the cost of treating a screen-detected case of CRC was the same as the cost of treating 
a symptomatic case detected at the same stage. These costs are presented in Table 3.587. 
 
Table 3.5.8: Lifetime costs of treating CRC  
Parameter name  Mean  Distribution used in PSA and 95% CI Source 
Lifetime cost of treatment - Dukes' A CRC  £ 12,455  Gamma(100,125)  (10,134-15,012) Pilgrim et al 2008 
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Lifetime cost of treatment - Dukes' B CRC  £ 17,137  Gamma(100,171)  (13,943-20,655) Pilgrim et al 2008 
Lifetime cost of treatment - Dukes' C CRC  £ 23,502  Gamma(100,235)  (19,122-28,327) Pilgrim et al 2008 
Lifetime cost of treatment - Stage D CRC  £ 25,703  Gamma(100,257)  (20,913-30,980) Pilgrim et al 2008 
 
A sensitivity analysis was performed on cost of treating CRC. With the increased use of expensive 
chemotherapy treatments, it is believed that the cost of treating CRC which was used in the model 
could be an underestimate, and in addition the cost of treating CRC is likely to increase significantly in 
future years. To reflect the possible increased costs, a sensitivity analysis was performed using these 
treatment costs +20%. 
 
3.5.10 Uptake of gFOBT in the English BCSP 
Uptake is defined as the proportion of individuals who attend a screening round (referred to as 
attenders or responders). Data on uptake is available for the first two rounds of the BCSP in England 
and this is shown in Table 3.5.9. Data from the NHS BCSP found that a small proportion of persons 
opted out from screening for clinical reasons or informed dissent after receiving an invitation. The 
current estimates of opt-out rates do not include persons who opt out after receiving a test kit. Data 
from the NHS BCSP on the total number of persons opting out was not available at the time of writing. 
 
Figure 3.5.1: Uptake of gFOBT screening in rounds one and two of the England BCSP
 
 
 
Table 3.5.9: Uptake of gFOBT screening in rounds one and two of the England BCSP 
 
 
 
The overall uptake data from screening round 2 is misleading, as the persons invited for round 2 
include a particularly high number of persons who attended round 1. Adjusting to account for this bias,  
the uptake for round 2 is estimated to be 55%, which is similar to that seen in round 1. A study of 
gFOBT screening in France reported participation rates of 52.8% for the first screening round and 
between 53.8% and 58.3% in rounds 2-6. (46) Based on these two data sources, a constant uptake 
rate is assumed in this analysis. 
 
When modelling just one round of screening, varying the uptake rate has little effect on cost 
effectiveness. This is because costs for non-attenders are very low, so an increase in uptake would 
lead to a proportional increase in both costs incurred and QALYs gained. In reality, however, the 
situation is more complex. For example, if we consider two scenarios both associated with 50% 
Screening
Round 1
Screening
Round 2
Screening
Round 3
Attend
Did not attend
Opt out
Attend
Did not attend
Opt out
?
Invited 6,074,725 1,070,246 396,056 674,190
Opted out from screening for 
clinical reasons or dissent 2,181        0.04% 317          0.03% 199           0.05% 117          0.02%
Invited and then sent test kit 6,072,544 100% 1,069,929 100% 395,857 7% 674,073 63%
Attended screening 3,195,533 53% 659,730   62% 77,794 20% 581,936 86%
Did not attend screening 2,877,011 47% 410,199   38% 318,063     80% 92,137      14%
Screening round 1 Screening round 2
Screening round 2,   
did not attend round 1
Screening round 2, 
attended round 1
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uptake: all persons attend 50% of screening rounds; and 50% of persons attend all screening rounds; 
we see that it is likely that these two scenarios will be associated with differing QALY gains. 
 
The modelling approach taken here partitions the population into subgroups according to their 
preference for screening: ³sometimes DWWHQG´ and ³never DWWHQG´.  The proportion of persons who 
sometimes attend and the attendance rate for this group was chosen so that the number of persons 
attending 0,1,or 2 of the first two rounds matches that seen in the current gFOBT screening 
programme. The model parameters and the fit of the model to attendance rates in rounds one and 
two are presented in Table 3.5.10. 
 
Table 3.5.10: Model for gFOBT uptake rates 
 
 
Uptake varies by gender, with higher uptake seen in men than in women. Uptake only varies slightly 
by age: women's uptake starts to fall off from about 65 years old whereas men's steadily increases. 
The modelling approach does not allow uptake to vary by age or gender. This simplification could be 
considered a limitation of the modelling approach. Further analysis of uptake data would allow a more 
sophisticated model of uptake to be considered in the future. 
 
 
3.5.11 Uptake rates for flexible sigmoidoscopy and iFOBT 
A pilot study in which FS screening was delivered as if it was a screening programme found that 45% 
attended, 5% accepted but were unable to attend within the time-frame of the study, 5% accepted but 
failed to attend, 7% declined, 27% did not respond, and 11% were ineligible or the invitation was 
returned unopened. Among those eligible to be screened, uptake was 51%. The programme was 
offered in two London Boroughs; one socioeconomically deprived and both ethnically diverse.  There 
were no gender differences in uptake, but rates were substantially higher in affluent (63%) than 
deprived areas (38%). (47) 
 
The study makes a comparison with FOBT uptake: ³Despite FS requiring bowel preparation, a visit to 
the hospital, and a more invasive test, uptake rates for the two tests seem surprisingly similar. Data 
from the London Screening Hub show FOBT kit return rates of 47% in Harrow and 40% in Brent, 
which are very close to the raw uptake rates of 53% and 39% in these boroughs in the FS pilot. 
Differences by deprivation were also similar. This suggests that the barriers to CRC screening are 
likely to lie not in the VSHFLILFVRIWKHWHVWEXWLQWKHSXEOLF¶VODFNRIDZDUHQHVVRIWKHKLJKLQFLGHQFHRI
CRC or the potential value of screening. This is encouraging for ultimately achieving uptake rates 
comparable to those in the established cancer screening programmes.´  
 
Based on this study we will use the same uptake rates for FS as has been seen in the current gFOBT 
BCSP. We will also assume that uptake for iFOBT is the same as for gFOBT. The Italian screening 
programme reports an average uptake rate of 47% for iFOBT and 27% for FS; however, these data 
Subgroup of screening population
Proportion of 
persons in subgroup
Attendance rate 
of subgroup
Never attend 0.37                       0%
Sometimes attend 0.63                       85%
Attendance rate for each round 54%
Screening attendance
gFOBT screening 
programme data Model
Attended rounds 1 and 2 0.45                       0.45                
Attended round 1 only 0.07                       0.08                
Attended round 2 only 0.09                       0.08                
Did not attend round 1 or 2 0.38                       0.38                
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related to different regions.(43) Based on this data, we will undertake a sensitivity analysis in which a 
lower uptake rate of 30% is assumed for FS. 
 
3.5.12 Deprivation 
Socioeconomic status (SES) affects CRC incidence and mortality rates. The SES gradient for CRC 
incidence is small. The National Cancer Intelligence Network reported a difference in age-
standardised incidence rates between the least and most deprived groups of 2.5 (41.2-43.8 per 
100,000). (48) As the incidence rate is slightly higher for the most deprived groups, the benefits 
associated with screening these groups will be slightly higher. To accurately model the benefits of 
screening for groups with different SES levels, data would be required on the relationship between 
SES and adenoma growth rates. Such data is not available.  
 
Uptake rates are known to vary by SES. The evaluation of the second round of the English bowel 
cancer screening pilot reported that uptake fell with increasing level of deprivation, from 61.2% to 
37.2% in IMD quintiles 1 to 5 respectively.(7) A sensitivity analysis in which a lower uptake rate is 
used to reflect one of the most deprived areas was undertaken. This demonstrates the comparative 
benefits of screening in the most deprived areas compared to the base case which represents 
England. 
 
3.5.13 Compliance with follow-up colonoscopy and surveillance colonoscopy 
Data from the NHS BCSP reports colonoscopy compliance rates of 79.1% for follow-up colonoscopy 
and 82.4% for persons invited for surveillance colonoscopy. (21) 
 
3.5.14 Utility values 
A utility value is a preference weight reflecting the relative value that individuals place on different 
health states. Here we use a different utility value for persons with CRC and for persons without CRC.  
 
A recent HTA of chemoprevention for colorectal cancer undertook a systematic review to identify 
relevant HRQoL literature. (49) The studies identified did not demonstrate a clear relationship 
between HRQoL and stage of cancer, treatment, phase of disease, or time since diagnosis.  
 
NICE recommends that utilities should be based upon public preferences (e.g. EQ-5D values) and 
valued by patients; three studies report such data. (26) A study by Ramsey et al, which was 
undertaken using 173 long-term survivors of bowel cancer (mean age 70), elicited preferences using 
the Health Utilities Index Mark 3 (HUI3) reported a mean utility score of 0.85 (SD=0.15). (50) The 
FOCUS trial included patients with metastatic bowel cancer undergoing chemotherapy and reported 
an EQ-5D value of 0.76 (0.72-0.80). (51) The MABEL study included patients with metastatic bowel 
cancer who had failed on at least one prior line of chemotherapy and reported a health utility EQ-5D 
value of 0.73. (52) 
 
The data available on utility values for CRC is very limited. The sample sizes are small, and two of the 
studies focus only on patients undergoing treatment. Some of the utility values reported are higher 
than the general population utility value for a person aged 75 of 0.75. (53) This inconsistency means 
that it is not possible to use age-adjusted utility values, and it is difficult to determine a without-CRC 
utility value to use. 
 
An analysis of EQ-5D data from the health survey for England reports a value of 0.697 (95% CI 
0.657-0.736) for persons with cancer and 0.798 (95% CI 0.755-0.839) for persons without cancer. 
(54) This data is limited by the fact that the health survey for England does not include persons in 
hospital or in nursing homes. Due to the problems mentioned with the CRC-specific data, this data will 
be used in the model here. 
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There may be a small utility decrement associated with undergoing a screening test; however, such a 
decrement is likely to only last a short period of time. There is no data available for utility values 
during a screening test, so no utility decrement due to screening test was included within the 
modelling.  
 
The uncertainty in the utility value data suggests that intermediate outcome measures such as cost 
per case avoided may be more reliable measures. 
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4 Results 
4.1 Optimal age for FS screening  
Data comparing the model results for one-off FS screening for a range of ages from 50 to 70 is 
presented in Table 4.1.1. FS screening at age 55 is associated with the greatest gain in QALYs; 
however, the QALY gains are very similar for screening ages of 52-58. The greatest reduction in CRC 
incidence and mortality is seen for screening at age 64. 
 
Table 4.1.1: One-off FS screening at different ages ± summary results 
 
 
 
4.2 Comparison of different screening options 
Several screening options were considered involving gFOBT, iFOBT and FS and the results of 12 
different screening strategies are presented in Table 4.2.1 and Figures 4.2.1-4.2.3.  
 
The strategies of biennial screening with gFOBT or iFOBT were cost-VDYLQJZKHQFRPSDUHGWR³QR
VFUHHQLQJ´. A strategy of biennial screening with iFOBT dominates (i.e. is less costly and more 
effective than) biennial screening with gFOBT. However, it is also associated with approximately three 
times the number of colonoscopies. 
 
The most cost effective strategy was FS at age 55 followed by biennial iFOBT screening for ages 56-
74 irrespective of whether the comparator was the current screening programme of biennial gFOBT 
60-74 or no screening. This strategy was associated with the greatest net monetary benefit and also 
Summary health and resource outcomes
Screening Strategy
Reduction in 
CRC 
incidence (%)
Reduction in 
CRC 
mortality (%)
 Reduction in 
CRC 
treatment 
costs (%) 
Number of 
flexible 
sigmoidoscopie
s undertaken
Number of 
colonoscopies 
(screening)
Number of 
colonoscopies 
(surveillance)
Number of 
deaths due to 
perforation
 Number 
needed to 
screen to 
prevent one 
case of CRC 
 Number 
needed to 
screen to 
save one life 
No screening 0.0% 0.0% 0.0% -                 -                  -                 -                 
FS age 50 6.9% 8.4% 7.3% 334,143          6,561              13,557            1.8                 118               155             
FS age 52 7.9% 9.6% 8.3% 331,899          7,506              15,507            2.0                 103               136             
FS age 54 8.8% 10.7% 9.3% 329,229          8,466              17,352            2.3                 92                 121             
FS age 55 9.2% 11.2% 9.8% 327,681          8,948              18,226            2.4                 87                 115             
FS age 56 9.6% 11.7% 10.2% 325,985          9,428              19,044            2.5                 84                 109             
FS age 57 9.9% 12.1% 10.6% 324,158          9,903              19,853            2.6                 80                 105             
FS age 58 10.2% 12.5% 11.0% 322,217          10,373            20,592            2.8                 77                 101             
FS age 59 10.5% 12.9% 11.3% 320,094          10,833            21,233            2.9                 75                 97               
FS age 60 10.7% 13.2% 11.6% 317,776          11,281            21,889            3.0                 73                 94               
FS age 62 11.1% 13.6% 12.0% 312,566          12,132            22,774            3.1                 70                 90               
FS age 64 11.2% 13.8% 12.2% 306,374          12,903            23,473            3.3                 67                 87               
FS age 66 11.1% 13.8% 12.2% 299,051          13,570            23,571            3.4                 67                 85               
FS age 68 10.7% 13.4% 11.9% 290,497          14,111            22,424            3.4                 67                 85               
FS age 70 10.1% 12.7% 11.4% 280,429          14,494            21,598            3.4                 68                 86               
*Model predictions correspond to a cohort of 618,900 50 year olds (the number in England in 2007)
Cost effectiveness: Discounted*
Cost per 
person LYs saved QALYs saved
Net Monetary 
Benefit 
(WTP=£20K)
No screening £593 19.352 15.4075 -                 -                  -                 -                 
FS age 50 £650 19.376 15.4276 £57 0.0236            0.0202            £346
FS age 52 £638 19.377 15.4285 £45 0.0246            0.0210            £376
FS age 54 £627 19.377 15.4289 £34 0.0250            0.0214            £394
FS age 55 £622 19.377 15.4289 £30 0.0251            0.0214            £399
FS age 56 £618 19.377 15.4288 £25 0.0250            0.0213            £401
FS age 57 £614 19.377 15.4285 £21 0.0247            0.0211            £400
FS age 58 £610 19.376 15.4282 £18 0.0243            0.0207            £396
FS age 59 £607 19.376 15.4277 £14 0.0237            0.0202            £390
FS age 60 £604 19.375 15.4271 £12 0.0231            0.0196            £381
FS age 62 £600 19.373 15.4256 £7 0.0214            0.0182            £357
FS age 64 £596 19.371 15.4239 £4 0.0194            0.0164            £325
FS age 66 £594 19.369 15.4220 £2 0.0171            0.0145            £288
FS age 68 £593 19.367 15.4199 £0 0.0147            0.0124            £248
FS age 70 £593 19.364 15.4178 £1 0.0123            0.0104            £207
*Costs and health benefits discounted at 3.5% per annum from age 50
Incrementals compared to no screening
Screening strategy Total cost per person
Total life 
years per 
person
Total QALYs 
per person
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the greatest reduction in CRC incidence, CRC mortality and CRC treatment costs. This strategy was 
also associated with the greatest endoscopy requirements of all the screening strategies considered 
requiring six times as many screening colonoscopies as the current programme. 
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Table 4.2.1: Screening strategies involving FOBT and FS ± summary results  
 
 
 
  
Screening Strategy
Reduction in 
CRC 
incidence (%)
Reduction in 
CRC 
mortality (%)
 Reduction in 
CRC 
treatment 
costs (%) 
Number of 
flexible 
sigmoidoscopie
s undertaken
Number of 
colonoscopies 
(screening)
Number of 
colonoscopies 
(surveillance)
Number of 
deaths due to 
perforation
 Number 
needed to 
screen to 
prevent one 
case of CRC 
 Number 
needed to 
screen to 
save one life 
No screening 0.0% 0.0% 0.0% -                 -                  -                 -                 
gFOBT at 60-69 (biennial) 6.5% 9.9% 8.0% -                 23,111            14,463            2.7                 570               595             
gFOBT at 60-74yrs (biennial) 9.2% 14.5% 11.6% -                 36,678            20,097            4.2                 617               621             
iFOBT at 60, 65, 70 yrs 9.8% 15.2% 12.1% -                 46,316            21,934            5.4                 224               230             
iFOBT at 60-69 (biennial) 14.4% 21.0% 17.2% -                 73,037            31,283            7.9                 256               279             
iFOBT at 60-74yrs (biennial) 19.3% 28.5% 23.4% -                 113,861           41,090            11.9               291               314             
FS age 55 9.2% 11.2% 9.8% 327,681          8,948              18,226            2.4                 87                 115             
FS age 55, 65 17.7% 21.5% 19.0% 630,012          19,064            35,895            5.0                 88                 114             
FS age 55, gFOBT 66-74 (biennial) 14.0% 19.1% 16.1% 327,681          31,781            28,731            4.9                 301               351             
FS age 55, iFOBT 66-74 (biennial) 20.1% 28.1% 23.6% 327,681          81,201            41,593            10.0               208               237             
FSIG age 55, iFOBT 60, 65,70 16.6% 22.4% 18.8% 327,681          52,263            34,680            6.9                 180               213             
FS age 55, iFOBT 60-74 (biennial) 24.7% 33.4% 28.4% 327,681          118,697           50,613            13.0               261               307             
FS age 55, iFOBT 56-74 (biennial) 26.4% 35.4% 30.2% 327,681          140,444           53,904            14.5               303               359             
Cost per 
person LYs saved QALYs saved
Net Monetary 
Benefit 
(WTP=£20K)
Incremental 
cost per 
person
Incremental 
LYs saved
Incremental 
QALYs 
saved
Net Monetary 
Benefit 
(WTP=£20K)
No screening £593 19.352 15.4075 -                 -                  -                 -                 £0 -              -              
gFOBT at 60-69 (biennial) £566 19.367 15.4196 -£26 0.0150            0.0122            £270
gFOBT at 60-74yrs (biennial) £558 19.371 15.4229 -£35 0.0192            0.0154            £343 -                -              -              -              
iFOBT at 60, 65, 70 yrs £556 19.374 15.4254 -£37 0.0222            0.0179            £395 -£2 0.003 0.003 £52
iFOBT at 60-69 (biennial) £541 19.384 15.4337 -£52 0.0323            0.0263            £577 -£17 0.013 0.011 £235
iFOBT at 60-74yrs (biennial) £530 19.391 15.4391 -£63 0.0389            0.0316            £695 -£28 0.020 0.016 £352
FS age 55 £622 19.377 15.4289 £30 0.0251            0.0214            £399 £65 0.006 0.006 £57
FS age 55, 65 £638 19.391 15.4405 £45 0.0387            0.0330            £615 £80 0.020 0.018 £272
FS age 55, gFOBT 66-74 (biennial) £606 19.385 15.4355 £13 0.0334            0.0280            £547 £48 0.014 0.013 £204
FS age 55, iFOBT 66-74 (biennial) £590 19.395 15.4433 -£2 0.0431            0.0359            £720 £33 0.024 0.020 £377
FSIG age 55, iFOBT 60, 65,70 £599 19.393 15.4416 £6 0.0408            0.0342            £677 £41 0.022 0.019 £335
FS age 55, iFOBT 60-74 (biennial) £581 19.406 15.4525 -£12 0.0540            0.0450            £912 £23 0.035 0.030 £569
FS age 55, iFOBT 56-74 (biennial) £582 19.412 15.4573 -£11 0.0597            0.0498            £1,007 £25 0.041 0.034 £665
Incrementals compared to no screening Incrementals compared to gFOBT at 60-74yrs (biennial)
Screening strategy Total cost per person
Total life 
years per 
person
Total QALYs 
per person
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Figure 4.2.1: Cost effectiveness plane, discounted 
 
 
 
 
Figure 4.2.2: Incremental cost effectiveness plane (compared to no screening), discounted 
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Figure 4.2.3: Incremental cost effectiveness plane (compared to biennial gFOBT 60-74), discounted
 
 
 
Economics of increasing screening awareness 
An analysis was performed to evaluate the economics of spending to increase screening awareness, 
which can increase uptake. An increase in uptake from 54% to 70% results in an increase in 
incremental QALYs of 0.004 and a decrease in incremental costs of £8 for the strategy gFOBT 60-74 
(biennial). Based on a willingness to pay threshold of £20,000, for an age cohort, it is cost effective to 
spend up to £88 per each person in the cohort (over the cohort¶s lifetime) on measures which will 
increase the uptake from 54% to 70%. 
 
 
4.3 Sensitivity analysis 
 
One-way sensitivity analyses 
A series of one-way sensitivity analyses were undertaken to investigate the impact on the model 
results of varying individual model parameters. The parameters considered were those for which 
there was thought to be considerable uncertainty surrounding estimates. A description of the reasons 
for the selection is included within the relevant parts of the model parameters section of this report. 
The results of the one-way sensitivity analyses undertaken are presented in Table 4.3.1 including 
LQFUHPHQWDOFRPSDUHGWRWKHFXUUHQWSURJUDPPHRIµJ)2%7ELHQQLDO-¶. 
 
Several sensitivity analyses were performed in relation to the costs used within the model. There is 
considerable uncertainty surrounding the cost of endoscopy, so three different analyses were 
performed in relation to these costs. The analysis undertaken using high estimates for endoscopy 
costs resulted in slightly increased costs for FOBT but significantly increased costs for the screening 
strategies involving FS. For example, the ICER for one-off FS at age 55 compared to the current 
screening almost doubled from £11K to £20K. 
 
An analysis was performed in which the cost of treating CRC was increased by 20% to reflect the 
possible costs associated with increased use of expensive chemotherapy regimens. This analysis 
resulted in an increase in total costs for all screening strategies. Under this analysis the strategy of 
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µ)6DJHL)2%7 56-ELHQQLDO¶LVFRVWVDYLQJFRPSDUHGWRWKHFXUUHQWVFUHHQLQJVWUDWHJ\The 
model results were not sensitive to changes to the pathology costs of +/- 20%. 
 
Three sensitivity analyses were performed on uptake rates. For FOBT and FS screening, a lower 
uptake of 37% (with 50% of persons never attending) was considered to reflect the lowest quintile of 
the IMD deprivation. Secondly, an uptake of 70% (with 20% never attending) was considered to 
reflect higher uptake following increased promotion of the BCSP. A lower uptake results in lower 
screening costs (as the costs of a person not attending screening are low) and also a smaller gain in 
QALYs, but the effect on the ICER is not significant.  The effect on the QALYs of a higher/lower 
uptake rate is significant.  An uptake rate of 37% compared to 54% results in 0.004 fewer QALYs per 
person. It follows that a higher uptake rate will be associated with significantly higher reductions in 
both incidence and mortality. 
 
Lastly, a sensitivity analysis was performed in which the uptake of FS was assumed to be 30%, to 
reflect the data from Italy which showed considerably lower uptake rates for FS compared to iFOBT. 
With this low uptake rate for FS, the QALY gains associated with one-off FS at age 55 are 
considerably less than those associated with the current strategy of gFOBT 60-74 biennial screening. 
However, even with this lower uptake rate for FS, the strategy of FS age 55 followed by biennial 
iFOBT 56-74 is the most cost effective. 
 
A sensitivity analysis was performed which varied the referral threshold for iFOBT. Three referral 
thresholds were considered 100ng/ml (the base case) and 150 and 200ng/ml. The data for these 
analyses were based on a study by Castigilone et al which reported positivity rates of 4.2%, 3.0% and 
2.4% respectively for these thresholds.{Castiglione, 2002 903 /id} Figure 4.2.4 shows that the higher 
iFOBT thresholds result  in reduced QALYs gains but little difference in costs. At the threshold of 
200ng/ml iFOBT 60-74 was associated with slightly greater benefits than one-off FS at age 55 and 
slightly less benefits than FS age 55 then gFOBT 66-74. 
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Table 4.3.1: Results of one-way sensitivity analyses (incremental costs and QALYs are compared to a 
strategy of no screening)  
 
 
 
 
 
Figure 4.2.4: Results of scenario analyses, marginal costs and effects compared to current screening 
policy  
No screening
QALYs Costs QALYs Costs QALYs Costs QALYs Costs ICER
BASECASE 15.407 £593 15.423 £558 15.439 530 0.016 -£28 -£1,737
Low FOBT & FS uptake (37% 
each round, 50% never attend) 15.407 £593 15.418 £569 15.430 548 0.012 -£21 -£1,727
High FOBT & FS uptake (70% 
at each round, 20% never 15.407 £593 15.427 £547 15.448 512 0.021 -£36 -£1,737
Lower FS uptake (FS uptake 
30%, FOBT uptake 54%) 15.407 £593 15.423 £558 15.439 530 0.016 -£28 -£1,737
High COL follow-up 
compliance (FOBT 90%, FS 15.407 £593 15.425 £553 15.442 524 0.017 -£29 -£1,729
Low COL follow-up compliance 
(FOBT 69%, FS 94%) 15.407 £593 15.421 £563 15.436 537 0.015 -£26 -£1,727
Life time costs treating CRC, 
+20% 15.407 £853 15.423 £783 15.439 721 0.016 -£62 -£3,841
Endoscopy costs - low values 15.407 £593 15.423 £552 15.439 514 0.016 -£38 -£2,361
Endoscopy costs - high values 15.407 £593 15.423 £566 15.439 552 0.016 -£14 -£863
Endoscopy costs - nurse led 
Derbyshire estimates 15.407 £593 15.423 £560 15.439 535 0.016 -£25 -£1,539
Pathology costs +20% 15.407 £593 15.423 £558 15.439 530 0.016 -£28 -£1,715
Pathology costs -20% 15.407 £593 15.423 £557 15.439 529 0.016 -£29 -£1,759
One-way sensitivity 
analyses
iFOBT at 60-74yrs (biennial)gFOBT at 60-74yrs (biennial)
Total per person 
(discounted)
Incr. 
compared to 
current Total per person (discounted)
Total per 
person 
(discounted)
QALYs Costs QALYs Costs ICER QALYs Costs QALYs Costs ICER QALYs Costs QALYs Costs ICER
BASECASE 15.429 622 0.006 £65 £10,659 15.435 606 0.013 £48 £3,824 15.457 582 0.034 £25 £712
Low FOBT & FS uptake (37% 
each round, 50% never attend) 15.422 613 0.004 £45 £11,342 15.427 602 0.009 £33 £3,838 15.444 582 0.026 £13 £521
High FOBT & FS uptake (70% at 
each round, 20% never attend) 15.435 631 0.008 £84 £10,522 15.444 610 0.016 £63 £3,821 15.471 581 0.044 £33 £756
Lower FS uptake (FS uptake 
30%, FOBT uptake 54%) 15.419 610 -0.003 £53 -£15,165 15.427 592 0.004 £34 £9,130 15.453 556 0.031 -£2 -£67
High COL follow-up compliance 
(FOBT 90%, FS 98%) 15.429 621 0.005 £68 £14,223 15.437 603 0.012 £50 £4,100 15.460 578 0.035 £25 £703
Low COL follow-up compliance 
(FOBT 69%, FS 94%) 15.428 623 0.007 £61 £8,213 15.434 610 0.013 £47 £3,550 15.455 588 0.034 £25 £746
Life time costs treating CRC, 
+20% 15.429 851 0.006 £68 £11,195 15.435 816 0.013 £33 £2,631 15.457 751 0.034 -£32 -£924
Endoscopy costs - low values 15.429 578 0.006 £26 £4,231 15.435 559 0.013 £6 £505 15.457 520 0.034 -£32 -£940
Endoscopy costs - high values 15.429 685 0.006 £119 £19,674 15.435 673 0.013 £107 £8,479 15.457 670 0.034 £104 £3,027
Endoscopy costs - nurse led 
Derbyshire estimates 15.429 586 0.006 £27 £4,418 15.435 571 0.013 £11 £907 15.457 552 0.034 -£7 -£217
Pathology costs +20% 15.429 623 0.006 £65 £10,709 15.435 607 0.013 £49 £3,856 15.457 584 0.034 £25 £737
Pathology costs -20% 15.429 622 0.006 £64 £10,609 15.435 605 0.013 £48 £3,792 15.457 581 0.034 £24 £686
One-way sensitivity analyses
FS age 55, gFOBT 66-74 (biennial)FS age 55 FS age 55, iFOBT 56-74 (biennial)
Total per 
person 
(discounted)
Incr. 
compared to 
current 
Total per 
person 
(discounted)
Incr. 
compared to 
current 
Total per 
person 
(discounted)
Incr. 
compared to 
current 
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The marginal cost-effectiveness plane displays the differences in expected costs and QALYs 
compared to the currently screening policy (gFOBT 60-74). The dotted grey lines radiating from the 
origin segment the cost-effectiveness plane by the willingness-to-pay thresholds indicated. Four 
different screening strategies are presented, compared to current screening which is at the origin. For 
each screening strategy the base case estimate of cost-effectiveness is represented by a white 
square. The effect of various scenarios and parameter values are described by the lines radiating 
from the base case. 
 
 
Probabilistic sensitivity analysis (PSA)  
A probabilistic sensitivity analysis was undertaken in which parameter values are all simultaneously 
sampled from the distributions, reflecting their uncertainty. The parameter values varied in the PSA 
and the distributions used are described in Appendix 4. The correlated parameter sets generated by 
the Metropolis-Hasting calibration were used to reflect the uncertainty in the natural history 
parameters and screening test characteristics estimated in the calibration process. This approach 
correctly represents the joint uncertainty in these parameters, which is particularly important because 
of the potential for correlation between several of these parameters. 
 
The results of the PSA are presented in a cost-effectiveness scatter plot and a cost-effectiveness 
acceptability curve; see Figures 4.3.1 and 4.3.2. At a ZLOOLQJQHVVWRSD\RI³FS at age 55, 
biennial iFOBT 66-´ had a 75% chance of being the most cost effective strategy. At a willingness to 
pay threshold of £15,000 or above, the straWHJ\RI³FS at age 55, biennial iFOBT 56-74´ had a 100% 
probability of being the most cost effective strategy.  
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Figure 4.3.1: PSA incremental cost-effectiveness plane scatter plot compared to no screening 
 
 
 
 
Figure 4.3.2: PSA Cost effectiveness acceptability curve 
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5 Conclusions 
 
All screening strategies evaluated were cost-effective when compared to no screening using a 
willingness to pay threshold of £20K per QALY. The strategies of biennial screening with gFOBT or 
iFOBT were cost-saving ZKHQFRPSDUHGWR³QRVFUHHQLQJ´. A strategy of biennial screening with 
iFOBT dominates (i.e. is less costly and more effective than) biennial screening with gFOBT; 
however, it is also associated with approximately three times the number of colonoscopies. For a 
strategy of one-off FS screening, the optimal effectiveness (QALYS) is achieved with a one-off FS 
screen at age in the range 55-60.  
 
The most cost effective strategy was FS at age 55 followed by biennial iFOBT screening for ages 56-
74, irrespective of whether the comparator was the current screening programme of biennial gFOBT 
60-74 or no screening. This strategy was associated with the greatest net monetary benefit and also 
the greatest reduction in CRC incidence, CRC mortality and CRC treatment costs. 
 
Sensitivity analyses demonstrated that the results were highly sensitive to several model parameters 
such as uptake, endoscopy costs and iFOBT threshold. However, in all of these analyses the most 
cost-effective screening strategy remained unchanged. 
 
The probabilistic sensitivity analysis examined uncertainty surrounding expected costs and QALYs. At 
a willingness to pay threshold of £4,000 or aboveWKHVWUDWHJ\RI³FS at age 55, biennial iFOBT 56-
74´ had a 100% probability of being the most cost-effective strategy. 
 
The analysis demonstrated that it may be cost-effective to spend considerable resources on 
increasing screening awareness.  
 
Areas of uncertainty 
 
The definitions used to classify persons with adenomas varied between the English screening data 
(FS and gFOBT) which classify persons as low/intermediate/high risk according to BSG guidelines 
and the German colonoscopy study which reported numbers of persons with advanced adenomas. In 
order to include both data sources within the modelling, an adjustment had to be made to estimate the 
proportion of advanced adenomas which would be classified as high risk. This adjustment was crude 
as it was based on a small dataset, so it introduces uncertainty into the modelling. 
 
The model predictions fit the data from the first round of gFOBT screening and the FS trial data very 
well. The model predicts a small decrease in HR adenoma detection rates at the second gFOBT 
screen; however, the data from the second screen showed a much higher decrease in HR adenoma 
detection rates. The second screen data was associated with a much higher false positive rate than 
seen at the first screen; however, the model predicts that the false positive rates will not vary 
significantly between the first and second screen. 
  
The difference between the gFOBT second screen data and the model predictions suggests that 
either: (1) the second screen data is in some way biased, or (2) gFOBT sensitivity and specificity vary 
by first/repeat screen which is not represented by our model structure. Possible sources of bias 
affecting the gFOBT first/second screen data are not well understood. Lower detection rates and 
higher false positive rates at a second/repeat screen would result in a strategy of repeated gFOBT 
being significantly less effective than is predicted by this model. This issue results in significant 
uncertainty surrounding the efficacy of the use of gFOBT for repeated screens.  
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Data on transition rates post-polypectomy was very limited, hence there is considerable uncertainty 
surrounding the modelling of surveillance. The model predictions for screening effectiveness were 
shown to be highly sensitive to this data. When detailed data on the outcomes at surveillance in the 
English gFOBT screening programme becomes available, this can be used to improve the accuracy 
of this area of the modelling. 
 
There is considerable uncertainty surrounding the comparative sensitivity of the screening tests in the 
distal and proximal colon. Due to data limitations, accurate modelling of the differing sensitivity 
between the proximal and distal colon was not possible.  
 
This analysis combined data from three different countries (England, Germany and Italy). Differences 
in adenoma and CRC prevalence between England, Germany and Italy may exist; however, the 
extent of these differences is unknown. The value of using data from more than one country is that it 
allows the use of large datasets from several different screening modalities. The benefit of including 
data on different screening modalities was considered to outweigh the uncertainty introduced by using 
datasets from different countries. 
 
 
 
6 Discussion/future priorities 
Cancer screening is an area where mathematical modelling is of great use. If data from several 
countries is considered, this provides large datasets for different screening modalities. As 
demonstrated here, modelling allows data from screening programmes of three different modalities to 
be used to produce predictions for a large range of screening options including various age ranges, 
screening intervals and screening strategies which combine more than one modality.  
 
This analysis was limited not by the need to run further screening trials, but by the availability of data 
from existing screening programmes. Collecting and reporting detailed, complete and comprehensive 
observational data from existing screening programmes should be a high priority for the future.  
 
Summary of currently available screening programme reporting: 
 The Italian screening programme produces an annual survey ³Screening for colorectal cancer 
in Italy´ 2004-2008.(43) Positivity and CRC/adenoma detection rates are reported by age and 
gender. Data is grouped into five-year age bands, and proximal and distal findings are not 
reported separately. 
 England produced a report of the first and second rounds of the Bowel cancer screening pilot 
but no report on rollout of entire screening programme.(7) Data on advanced 
adenomas/tubulovillous adenomas has been collected but is not available. Data on finds at 
surveillance is not yet available separated according to the patient¶s classified risk level 
following screening. 
 Brenner has produced several interesting papers which provide insight into the natural history 
of CRC using the results of survey of screening colonoscopies in Germany. (15, 18) No paper 
has been identified that reports a complete summary of screening findings for the German 
programme. 
 Scotland produces a report of key performance indicators. (55) 
 
Reporting and availability of complete information from existing screening programmes is essential to 
enable accurate modelling and to increase the understanding of the natural history of CRC. 
Information of use includes linked data on patient characteristics (age, sex, racial background, 
socioeconomic status), number of screens attended, screening and surveillance outcomes: 
attendance, adenomas detected (location, size, number, type, advanced/non-advanced), CRC 
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detected (stage and location). The sharing of such complete information may require a departure from 
the traditional constraints of presenting results in small two-dimensional tables in journal articles.  
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7 Appendices 
 
 
7.1 Appendix 1: Adenoma prevalence by age in an average risk population: A 
systematic review of adenoma detection rates from colonoscopy screening and 
autopsy studies ± available in separate file. 
 
7.2 Appendix 2: Calibration method and results 
Figures A2.1 and A2.2 illustrate the calibration method used. A full description of the calibration 
method is included in the paper by Whyte et al. (13) 
 
Figure A2.1: CRC model calibration method 
 
 
 
Figure A2.2: Metropolis-Hastings algorithm illustrated for a 2-dimensional parameter space 
The aim is to find values for the two parameters which minimise the difference between the model 
predictions and the observed data; this is the lowest point region on the surface. 
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Figure A2.3 Correlation matrix for parameters estimated within model calibration process 
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Normal epithelium to LR adenomas - age 30 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Normal epithelium to LR adenomas - age 50 0.86- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Normal epithelium to LR adenomas - age 70 0.16 0.48- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Normal epithelium to LR adenomas - age 100 0.02 0.16- 0.19 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
LR adenomas to high risk adenomas - age 30 0.11- 0.33 0.86- 0.16 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
LR adenomas to high risk adenomas - age 50 0.02- 0.26- 0.91 0.11- 0.97- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
LR adenomas to high risk adenomas - age 70 0.20 0.08 0.82- 0.01- 0.90 0.93- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
LR adenomas to HR adenomas - age 100 0.35 0.04- 0.69- 0.14- 0.75 0.78- 0.91 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
HR adenomas to Dukes A CRC - age 30 0.08 0.30- 0.87 0.27- 0.90- 0.94 0.80- 0.58- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
HR adenomas to Dukes A CRC - age 50 0.40 0.57- 0.73 0.09- 0.59- 0.63 0.34- 0.15- 0.75 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
HR adenomas to Dukes A CRC - age 70 0.66 0.55- 0.04 0.10 0.24 0.24- 0.51 0.66 0.02- 0.50 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
HR adenomas to Dukes A CRC - age 100 0.13 0.40- 0.93 0.14- 0.95- 0.97 0.87- 0.70- 0.96 0.71 0.08- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Normal epithelium to CRC Dukes A 0.07- 0.25 0.67- 0.25 0.60 0.70- 0.53 0.33 0.82- 0.76- 0.13- 0.73- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Preclinical CRC: Dukes A to Dukes B 0.47 0.18- 0.55- 0.32- 0.58 0.63- 0.84 0.92 0.40- 0.06 0.74 0.51- 0.19 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Preclinical CRC: Dukes B to Dukes' C 0.14 0.44- 0.99 0.10 0.88- 0.93 0.83- 0.68- 0.92 0.75 0.02 0.96 0.72- 0.54- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Preclinical CRC: Dukes C to Stage D 0.08 0.38- 0.97 0.12 0.86- 0.93 0.82- 0.67- 0.90 0.74 0.00 0.93 0.71- 0.55- 0.98 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Symptomatic presention w ith CRC Dukes A 0.38 0.06- 0.67- 0.37- 0.65 0.70- 0.87 0.92 0.49- 0.09- 0.62 0.60- 0.28 0.98 0.65- 0.67- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Symptomatic presention w ith CRC Dukes B 0.24- 0.09- 0.83 0.06 0.87- 0.92 0.98- 0.93- 0.80 0.37 0.49- 0.86 0.56- 0.86- 0.85 0.85 0.90- 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Symptomatic presention w ith CRC Dukes C 0.63- 0.43 0.24 0.01 0.45- 0.47 0.72- 0.83- 0.25 0.30- 0.94- 0.32 0.05- 0.90- 0.26 0.28 0.82- 0.72 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   -   
Symptomatic presention w ith CRC Dukes D 0.69- 0.64 0.26- 0.05- 0.01- 0.00 0.31- 0.49- 0.21- 0.68- 0.96- 0.15- 0.30 0.63- 0.24- 0.23- 0.49- 0.29 0.87 1.00 -   -   -   -   -   -   -   -   -   -   -   -   -   
gFOBT Sensitivity for LR adenomas 0.18- 0.42 0.94- 0.11- 0.84 0.88- 0.81 0.64 0.86- 0.67- 0.01- 0.90- 0.68 0.53 0.93- 0.90- 0.63 0.80- 0.25- 0.21 1.00 -   -   -   -   -   -   -   -   -   -   -   -   
gFOBT Sensitivity for HR adenomas 0.16 0.12- 0.13- 0.06 0.14 0.21- 0.20 0.19 0.18- 0.01- 0.18 0.17- 0.18 0.17 0.13- 0.14- 0.16 0.20- 0.17- 0.11- 0.13 1.00 -   -   -   -   -   -   -   -   -   -   -   
gFOBT Sensitivity for CRC 0.49- 0.51 0.24- 0.48- 0.13- 0.09 0.22- 0.31- 0.01 0.38- 0.72- 0.01- 0.08 0.28- 0.19- 0.19- 0.15- 0.19 0.59 0.69 0.20 0.14- 1.00 -   -   -   -   -   -   -   -   -   -   
gFOBT Specif icity age 50 0.36 0.49- 0.74 0.24- 0.69- 0.72 0.49- 0.23- 0.85 0.85 0.35 0.79 0.77- 0.05- 0.78 0.78 0.17- 0.48 0.13- 0.53- 0.75- 0.07- 0.25- 1.00 -   -   -   -   -   -   -   -   -   
gFOBT Specif icity age 70 0.19- 0.41 0.93- 0.05 0.86 0.90- 0.75 0.54 0.95- 0.80- 0.13- 0.93- 0.77 0.38 0.94- 0.94- 0.49 0.75- 0.14- 0.35 0.90 0.13 0.18 0.90- 1.00 -   -   -   -   -   -   -   -   
FS Sensitivity for LR adenomas 0.26- 0.44 0.69- 0.24- 0.63 0.61- 0.61 0.55 0.54- 0.44- 0.07 0.65- 0.36 0.48 0.68- 0.67- 0.56 0.60- 0.25- 0.09 0.64 0.00- 0.16 0.47- 0.59 1.00 -   -   -   -   -   -   -   
FS Sensitivity for HR adenomas 0.10 0.07 0.62- 0.15 0.62 0.68- 0.63 0.50 0.73- 0.44- 0.15 0.67- 0.62 0.43 0.68- 0.68- 0.48 0.67- 0.34- 0.01 0.61 0.20 0.06- 0.52- 0.65 0.42 1.00 -   -   -   -   -   -   
FS Sensitivity for CRC 0.27 0.02- 0.45- 0.05- 0.56 0.57- 0.68 0.69 0.42- 0.01 0.56 0.49- 0.20 0.72 0.47- 0.44- 0.71 0.71- 0.68- 0.46- 0.39 0.18 0.26- 0.07- 0.31 0.39 0.52 1.00 -   -   -   -   -   
iFOBT Sensitivity for LR adenomas 0.20- 0.29 0.46- 0.05- 0.44 0.42- 0.32 0.22 0.41- 0.42- 0.14- 0.44- 0.24 0.12 0.44- 0.44- 0.19 0.30- 0.03 0.26 0.43 0.13 0.14 0.39- 0.44 0.36 0.24 0.18 1.00 -   -   -   -   
iFOBT Sensitivity for HR adenomas 0.15 0.16- 0.04 0.36- 0.19- 0.11 0.00- 0.11 0.16 0.21 0.12 0.13 0.07- 0.19 0.06 0.04 0.17 0.03- 0.13- 0.15- 0.02- 0.09 0.03 0.06 0.03- 0.11 0.06- 0.08- 0.10- 1.00 -   -   -   
iFOBT Sensitivity for CRC 0.52- 0.51 0.24- 0.57- 0.17- 0.12 0.28- 0.34- 0.02 0.42- 0.80- 0.02 0.07 0.34- 0.18- 0.20- 0.21- 0.23 0.67 0.78 0.18 0.13- 0.80 0.30- 0.23 0.16 0.07- 0.39- 0.15 0.21 1.00 -   -   
iFOBT Specif icity age 50 0.07 0.10- 0.21 0.00- 0.15- 0.15 0.13- 0.04- 0.20 0.26 0.13 0.19 0.19- 0.00- 0.21 0.22 0.03- 0.12 0.05- 0.17- 0.20- 0.15 0.07- 0.18 0.20- 0.10- 0.06- 0.18 0.05- 0.17 0.13- 1.00 -   
iFOBT Specif icity age 70 0.07- 0.14 0.47- 0.04 0.40 0.42- 0.35 0.21 0.48- 0.43- 0.11- 0.45- 0.38 0.12 0.48- 0.49- 0.18 0.34- 0.01- 0.24 0.46 0.03 0.06 0.37- 0.46 0.23 0.35 0.03- 0.25 0.21- 0.15 0.65- 1.00 
* Pairs of parameters w ith correlation of magnitude greater than 0.8 are shaded in grey
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7.3 Appendix 3 Systematic review and Bayesian meta-analysis of the sensitivity and 
specificity of immunochemical FOBT 
 
A systematic review and meta-analysis was undertaken to obtain estimates for the test characteristics 
of immunochemical faecal occult blood tests (iFOBT).  More specifically, this assessment updates and 
extends the systematic review conducted by Burch et al.,(39) which included studies up to November 
2004.  As the iFOBT Evaulation Report produced by the Centre for Evidence-based Purchasing 
concluded that the OC-Sensor / DIANA analyser was the most suitable system for the English BCSP, 
the review was limited to the OC-Sensor test. Full details of the search strategy and studies found are 
provided in the separate appendix file. 
  
Summary of results from individual studies 
Sensitivity and specificity of iFOBT for the detection of all neoplasms ranged from 5.4%(56) to 
19.8%(57) and 91.6%(58) to 98.5%(56) respectively, when data was derived from cohort studies. 
Case-control studies generally reported higher sensitivities, ranging from 38.9%(59) to 68.9%(60) and 
specificity ranging from 93.9%(61) to 98.3%.(62)  A higher sensitivity for the detection of CRC was 
observed ranging from 23.7%(63) to 91.0%(64) and specificity ranged from 77.1%(65) to 98.9%.(66)  
For all adenomas, the sensitivity ranged from 4.4%(56) to 91.0%(67) and specificity ranged from 
42.8%(67) to 98.5%.(56)  Only one study(68) reported sensitivity and specificity values for adenomas 
of 1cm or larger.  Twelve studies did not report the haemoglobin threshold; however, the five studies 
which did report the haemoglobin threshold ranged from 30 ng/ml to 200 ng/ml.(65)  A study by 
Chen(65) assessed the optimal cut-off of iFOBT by using cost-effectiveness analysis and concluded 
that 110 ng/ml as the optimal cut-off of iFOBT for CRC screening.    
  
Bayesian meta-analysis of the sensitivity and specificity of immunochemical FOBT (iFOBT) 
The data for all neoplasms, colorectal cancer and adenomas were analysed separately using a 
Bayesian bivariate random effects model based on the model presented by Reitsma et al.(69)  The 
advantage of the Bayesian approach compared to the Classical approach is that it allows for 
uncertainty in the between-study standard deviation.  The model allows for correlation between 
sensitivity and specificity on the logit scale.  Posterior results are presented for sensitivity, specificity 
in Table A3.1.  Summary statistics are presented from the joint posterior distribution including: mean, 
SD, median, 2.5%-ile and 95%-ile. 
 
Samples from the joint posterior distribution were used within the probabilistic sensitivity analysis of 
the decision analytic model to preserve the properties of the joint posterior distribution. 
 
Table A3.1: Posterior Results of Bayesian meta-analysis of the sensitivity and specificity of iFOBT 
Parameter Mean (SD) 2.5%-ile, median, 97.5%-ile 
Sensitivity (adenomas) 0.27 (0.204) 0, 0.23, 0.75 
Sensitivity (CRC) 0.59 (0.219) 0.061, 0.64, 0.9 
Specificity (CRC and adenomas) 0.95 (0.013) 0.92, 0.95, 0.97 
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7.4 Appendix 4: Table of model inputs 
 
 
 
Parameter name  Mean Distribution used in PSA and 95% CI Source
Harm/complications parameters
COL (w ithout polypectomy) perforation rate 0.0% N/A FS UK screening trial data, Atkin et al 
COL (w ith polypectomy) perforation rate 0.3% Beta(4,1,427)  (0.00-0.01) Bow el cancer screening pilot 2nd round 
COL Probability of death follow ing perforation 5.2% Beta(4,73)  (0.01-0.11) Gatto et al 2003
FS (w ithout polypectomy) perforation rate 0.0% N/A FS UK screening trial data, Atkin et al 
FS (w ith polypectomy) perforation rate 0.01% Beta(1,9,498)  (0.00-0.00) FS UK screening trial data, Atkin et al 
FS Probability of death follow ing perforation 6.5% Beta(2,29)  (0.01-0.17) Gatto et al 2003
FS probability of hospitalisation for bleeding 0.03% Beta(12,40,609)  (0.00-0.00) FS UK screening trial data, Atkin et al 
COL probability of hospitalisation for bleeding 0.3% Beta(7,2,040)  (0.00-0.01) FS UK screening trial data, Atkin et al 
Repeat rates
gFOBT mean number of tests completed         1.08 N/A Asumption based on number of gFOBTs 
iFOBT mean number of tests completed         1.01 N/A
NHS BCSP data, Italian iFOBT screening 
programme Zorzi et al 2009
FS Probability test repeated on a later day         0.02 Beta(839,39,782)  (0.02-0.02) FS UK screening trial data, Atkin et al 
COL repeat test rate         0.07 Beta(5,453,72,858)  (0.07-0.07) NHS BCSP data
Screening participation parameters
FOBT participation for each screening round         0.54 Beta(1,080,920)  (0.52-0.56) NHS BCSP data
Proportion completing at least one FOBT screening 
round         0.63 Beta(63,37)  (0.53-0.72) NHS BCSP data
FOBT participation for a round for those w ho 
comply w ith at least one FOBT test         0.85 N/A NHS BCSP data
COL follow -up compliance FOBT screening         0.79 Beta(46,288,12,242)  (0.79-0.79) NHS BCSP data
COL follow -up compliance FS screening         0.96 Beta(2,047,79)  (0.95-0.97)
FS UK screening trial data, Atkin et al 
2002
COL surveilance compliance         0.83 N/A NHS BCSP data
FS screening compliance         0.85 N/A
Assumed same as for FOBT, Atkin et al 
2010
Health-related quality of life parameters
Utility value cancer free         0.80 Beta(279,71)  (0.75-0.84) Ara et al 2010
Utility value CRC         0.70 Beta(361,157)  (0.66-0.74) Ara et al 2010
Resource Use parameters
Cost of gFOBT screen (non-compliers)  £     2.03  Uniform(1.83,2.23) Southern hub screening costings model
Cost of gFOBT screen (normal result)  £     3.36  Uniform(3.03,3.70) Southern hub screening costings model
Cost of gFOBT screen (positive result)  £   11.94  Uniform(10.74,13.13) Southern hub screening costings model
Cost of iFOBT screen (non-compliers)  £     6.43  Uniform(5.79,7.07) Southern hub screening costings model
Cost of iFOBT screen (normal result)  £     7.37  Uniform(6.63,8.11) Southern hub screening costings model
Cost of iFOBT screen (positive result)  £   16.20  Uniform(14.58,17.82) Southern hub screening costings model
Cost of FS screen excl. FS exam (non-compliers)  £     5.02  Uniform(4.52,5.53) Southern hub screening costings model
Cost of FS screen excl. FS exam (not referred to 
COL)  £     6.01  Uniform(5.41,6.61) Southern hub screening costings model
Cost of FS screen excl. FS exam (referred to COL)  £   14.84  Uniform(13.36,16.32) Southern hub screening costings model
Cost of FS (w ithout polypectomy)  £      186  Uniform(167,205) 
NHS reference costs, screening centre 
estimates
Cost of FS (w ith polypectomy)  £      195  Uniform(176,215) 
NHS reference costs, screening centre 
estimates
Proportion of LR adenomas being referred for COL 
follow ing FS 3%  Uniform(0.02,0.05) FS trial data
Cost of COL (w ithout polypectomy)  £      205  Uniform(185,226) 
NHS reference costs and screening 
centre estimates
Cost of COL (w ith polypectomy)  £      237  Uniform(213,261) 
NHS reference costs and screening 
centre estimates
Cost of treating bow el perforation (major surgery)  £   2,164  Gamma(117,18)  (1,790-2,573) NHS reference costs
Cost of admittance for bleeding (overnight stay on 
medical w ard)  £      278  Gamma(193,1)  (240-319) NHS reference costs
Pathology cost for adenoma  £        26  Gamma(81,0)  (21-33) NHS reference costs 08/09, 
Pathology cost for cancer  £        26  Gamma(81,0)  (21-33) NHS reference costs 08/09, 
Lifetime cost - screen-detected Dukes' A  £ 12,455  Gamma(100,125)  (10,134-15,012) Pilgrim et al 2008
Lifetime cost - screen-detected Dukes' B  £ 17,137  Gamma(100,171)  (13,943-20,655) Pilgrim et al 2008
Lifetime cost - screen-detected Dukes' C  £ 23,502  Gamma(100,235)  (19,122-28,327) Pilgrim et al 2008
Lifetime cost - screen-detected Stage D  £ 25,703  Gamma(100,257)  (20,913-30,980) Pilgrim et al 2008
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Parameter name  Mean Distribution used in PSA and 95% CI Source
Test Characteristics
gFOBT Sensitivity for LR adenomas         0.01 Correlated parameter set  (0.009-0.010) Model calibration
gFOBT Sensitivity for HR adenomas         0.12 Correlated parameter set  (0.121-0.125) Model calibration
gFOBT Sensitivity for CRC         0.24 Correlated parameter set  (0.233-0.253) Model calibration
gFOBT Specif icity age 50         0.99 Correlated parameter set  (0.991-0.995) Model calibration
gFOBT Specif icity age 70         0.97 Correlated parameter set  (0.972-0.978) Model calibration
FS Sensitivity for LR adenomas         0.22 Correlated parameter set  (0.212-0.229) Model calibration
FS Sensitivity for HR adenomas         0.71 Correlated parameter set  (0.685-0.742) Model calibration
FS Sensitivity for CRC         0.62 Correlated parameter set  (0.612-0.741) Model calibration
FS Specif icity         1.00 N/A Assumption due to nature of the test
iFOBT Sensitivity for LR adenomas         0.05 Correlated parameter set  (0.043-0.047) Model calibration
iFOBT Sensitivity for HR adenomas         0.32 Correlated parameter set  (0.315-0.332) Model calibration
iFOBT Sensitivity for CRC         0.63 Correlated parameter set  (0.606-0.646) Model calibration
iFOBT Specif icity age 50         0.98 Correlated parameter set  (0.971-0.978) Model calibration
iFOBT Specif icity age 70         0.93 Correlated parameter set  (0.919-0.937) Model calibration
COL Sensitivity for LR adenomas         0.77 Beta(544,167)  (0.73-0.80) Van Rijn et al 2006
COL Sensitivity for HR adenomas         0.98 Beta(94,2)  (0.94-1.00) Van Rijn et al 2006
COL Sensitivity for CRC         0.98 Beta(94,2)  (0.94-1.00) Bressler et al 2007
COL Specif icity         1.00 N/A Assumption due to nature of the test
Natural history parameters
Normal epithelium to LR adenomas - age 30       0.021 Correlated parameter set  (0.020-0.022) Model calibration
Normal epithelium to LR adenomas - age 50       0.020 Correlated parameter set  (0.019-0.021) Model calibration
Normal epithelium to LR adenomas - age 70       0.045 Correlated parameter set  (0.029-0.047) Model calibration
Normal epithelium to LR adenomas - age 100       0.011 Correlated parameter set  (0.005-0.031) Model calibration
LR adenomas to high risk adenomas - age 30       0.009 Correlated parameter set  (0.007-0.014) Model calibration
LR adenomas to high risk adenomas - age 50       0.008 Correlated parameter set  (0.006-0.008) Model calibration
LR adenomas to high risk adenomas - age 70       0.008 Correlated parameter set  (0.008-0.010) Model calibration
LR adenomas to HR adenomas - age 100       0.004 Correlated parameter set  (0.003-0.010) Model calibration
HR adenomas to Dukes A CRC - age 30       0.029 Correlated parameter set  (0.004-0.031) Model calibration
HR adenomas to Dukes A CRC - age 50       0.025 Correlated parameter set  (0.022-0.026) Model calibration
HR adenomas to Dukes A CRC - age 70       0.054 Correlated parameter set  (0.050-0.058) Model calibration
HR adenomas to Dukes A CRC - age 100       0.115 Correlated parameter set  (0.084-0.118) Model calibration
Normal epithelium to CRC Dukes A       0.000 Correlated parameter set  (0.000-0.000) Model calibration
Preclinical CRC: Dukes A to Dukes B       0.508 Correlated parameter set  (0.501-0.886) Model calibration
Preclinical CRC: Dukes B to Dukes' C       0.692 Correlated parameter set  (0.499-0.702) Model calibration
Preclinical CRC: Dukes C to Stage D       0.708 Correlated parameter set  (0.594-0.728) Model calibration
Symptomatic presentation w ith CRC Dukes A       0.044 Correlated parameter set  (0.043-0.070) Model calibration
Symptomatic presentation w ith CRC Dukes B       0.176 Correlated parameter set  (0.124-0.180) Model calibration
Symptomatic presentation w ith CRC Dukes C       0.369 Correlated parameter set  (0.303-0.394) Model calibration
Symptomatic presentation w ith CRC Dukes D       0.735 Correlated parameter set  (0.647-0.923) Model calibration
Proportion of cancer incidence classif ied as 
proximal       0.380 N/A Cancer Registrations 2007, England
Average number of adenomas present in patient 
w ith at least one adenoma       1.900 N/A Winaw er et al 1993
Proportion of advanced adenomas classif ied as 
HR adenomas       0.746 N/A FS trial data
Proportion of HR pp requiring annual surveillence       0.290 N/A NHS BCSP data
LR polypectomy, transition probability LR       0.100 N/A England BCSP data, Martinez et al 
LR polypectomy, transition probability HR       0.040 N/A England BCSP data, Martinez et al 
IR polypectomy, transition probability LR       0.163 N/A England BCSP data, Martinez et al 
IR polypectomy, transition probability HR       0.091 N/A England BCSP data, Martinez et al 
HR polypectomy, transition probability LR       0.188 N/A England BCSP data, Martinez et al 
HR polypectomy, transition probability HR       0.568 N/A England BCSP data, Martinez et al 
FS= flexible sigmoidoscopy, COL=colonoscopy, FOBT=faecal occult blood test, LR=low  risk, IR=intermediate risk, HR=high risk
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